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ROLE OF TALIN1 PHOSPHORYLATION IN β1 INTEGRIN
ACTIVATION AND PROSTATE CANCER METASTASIS

Jung-Kang Jin, M.S.
Supervisory Professor: Gary E. Gallick, Ph.D.

Talins are adaptor proteins that regulate focal adhesion signaling by conjugating
integrins to the cytoskeleton. Talins directly bind and activate integrins but the
mechanism by which this occurs is unknown. As integrin activation and overexpression
of talins promote prostate cancer metastasis, understanding the mechanism by which
talins activate integrins will better elucidate their roles in Prostate cancer metastasis.
Phosphorylation of talins on serine 425 has been associated with β1 integrin functions.
Work in this dissertation tested the hypothesis that increased talin1 S425 phosphorylation
was required for β1 integrin activation and promotion of prostate cancer metastasis.
I first used shRNA to knockdown talins and demonstrated that talin1, but not
talin2, is required for β1 integrin activation. Furthermore, talin1 S425 phosphorylation,
but not total talin1 expression, correlated with metastatic potential of cultured prostate
cancer cells. To directly test whether talin1 phosphorylation activates β1 integrins, I
generated talin1 S425 mutants. Expressing a non-phosphorylatable mutant, talin1S425A in
talin1-silenced PC3-MM2 and C4-2B4 prostate cancer cells decreased β1 integrin
activation, adhesion, motility, and increased the sensitivity of cells to anoikis. In contrast,
re-expression of the phosphorylation-mimicking mutant, talin1S425D led to increased β1
integrin activation and generated biologic effects opposite to talin1S425A expression.
v

Mechanistically, I demonstrated that increased Cdk5 kinase activity correlates with
expression of its activator p35, and is responsible for talin1 phosphorylation and β1
integrin activation.
Next, I demonstrated that talin1 phosphorylation is required for Prostate cancer
bone metastasis in vivo. In the metastatic PC3-MM2 cells, expression of a nonphosphorylatable mutant, talin1S425A, in talin1-silenced PC3-MM2 cells, abolished their
ability to colonize in bone following intracardiac injection, while re-expression of
phosphorylation-mimicking mutant, talin1S425D restored their ability to metastasize to
bone. I further demonstrated by immunohistochemical staining that talin phosphorylation
is significantly increased in human bone metastases when compared to normal tissues,
primary tumors, or lymph node metastases, demonstrating the clinical relevance of talin
S425 phosphorylation.
In summary, I have identified a novel signaling pathway whereby overexpression
of p35 leads to increased Cdk5 activity, resulting in talin phosphorylation and β1 integrin
activation. This signaling axis is responsible for increased metastatic potential of prostate
cancer cells. Therefore, talin1, Cdk5 and p35 may be new targets for development of
therapies for prostate cancer bone metastasis.
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Chapter 1
Introduction
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Prostate cancer is the second most common type of cancer in men in the United
States. The American Cancer Society estimates that approximately 233,000 men will be
diagnosed of prostate cancer with an estimated 29,500 deaths in 2014 [1]. Many risk
factors are associated with prostate cancer, including increasing age, family history and
race [1-4]. For example, the incidence of rates of prostate cancer are especially higher
(~60%) in African Americans than in non-Hispanic whites [1, 5]. Other factors such as
high fat diet and obesity may also increase the risk of developing prostate cancer [6].
However, the molecular mechanisms by which these risk factors contribute to prostate
cancer are still not clear, and thus effective strategies to prevent the occurrence of
prostate cancer are also lacking.

Unfortunately, men with early prostate cancer usually have no symptoms. Only
when the disease advances, patients may have symptoms such as interrupted urine flow,
inability to urinate or pain with urination. Therefore, detection of prostate cancer before
these symptoms develop is critical to prevent cancer progression. Currently, the method
commonly used to detect early prostate cancer is the prostate-specific antigen (PSA)
blood test. PSA is secreted by cells in the prostate glands and can measured by ELISA
from blood samples. An increased level of PSA concentration higher than 4 ng/ml
indicates a higher chance of having prostate cancer [7, 8]. However, PSA levels can also
be increased by other factors, such as medicines, and increasing age. On the contrary, a
PSA level below 4 ng/ml does not absolutely indicate that men do not have prostate
cancer [1, 8]. In addition, results of clinical trials of using the PSA test to screen men,
thereby reducing prostate cancer are inconsistent. While two European trials of PSA
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screening have been reported to reduce mortality about 20~30% [9, 10], one US study
has found no reduction in mortality [8, 11]. Based on these results, there are insufficient
data to recommend for or against PSA screening for detecting early prostate cancer.
Although the use of PSA test for screening early prostate cancer is still controversial [8],
the American Cancer Society recommends that men at age 50 should discuss with their
health care provider the benefits and limitations of PSA testing [1]. Men at high risk of
developing prostate cancer, for example African Americans, should consult their health
care provider beginning at age 45 or even earlier [1].

Patients with early stage prostate cancer usually have only local tumors and can
be cured by surgery, external beam radiation or radioactive seed implants. The five-year
survival rate for localized prostate cancer is close to 100% [1]. However, when metastasis
has developed, the five-year survival rate decreases to 28% [1]. Prostate cancer can
metastasize to multiple distant organs such as the lungs, liver and brain, but it has a high
propensity for metastasizing to the bone. Bubendorf et. al. reported that 80% of the men
who had died from prostate cancer had bone metastases [12]. Most current treatments for
patients with bone metastases have little effect on improving long-term survival [13, 14].
Therefore, gaining a better understanding of cancer progression to bone metastasis and
the mechanisms by which prostate cancer cells metastasize to the bone are critical to
develop reagents and therapies for prostate cancer metastasis.
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Genetic alterations in prostate cancer
Prostate cancer metastasis occurs as results of accumulation of genetic and
epigenetic alterations in tumor cells. In regard to genetic alterations in prostate cancer,
extensive genomic analyses have identified many copy number alterations and
chromosomal rearrangements. Several somatic alterations including, gain of chromosome
8q and losses at chromosomes 3p, 8p, 10q, 13q, and 17p have been identified by
comparative genomic hybridization (CGH) [15, 16]. Many key regulatory genes are
located within these region, including NKX3.1 at 8p21, MYC at 8q24 and PTEN at 10q23,
and their roles in prostate cancer will be discussed below.

NKX3.1 down-regulation
Recent analyses have demonstrated that expression of NKX3.1, a tumor
suppressor gene, is downregulated in nearly all prostate cancers and metastases [17].
NKX3.1 has been shown to be a critical regulator of prostate epithelial differentiation.
Deletion of a single NKX3.1 allele (NKX3.1+/-) or complete knockout (NKX3.1-/-) in
prostate epithelial results in hyperplasia and dysplasia in mice at 1 year of age [18]. In
older mice with NKX3.1 knockout (between 1 and 2 years of age), the prostate glands
display more severe histopathological alterations resembling human prostate
intraepithelial neoplasia (PIN) [19, 20]. Nkx3.1 null mutant mice recapitulate early stages
of prostate carcinogenesis [20]. Therefore, these findings are consistent with the tumor
suppressor activity of NKX3.1, suggesting that NKX3.1 represents as a gatekeeper gene
for prostate cancer initiation [17, 21].
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MYC up-regulation
The 8q24 chromosomal region containing the MYC oncogene is often amplified in
advanced prostate tumors suggesting that MYC plays a role in late stage prostate cancer
[22]. However, studies of prostate cancer have also showed increased MYC mRNA in
low grade (e.g. Gleason score 6) tissues. Overexpression of MYC has been observed in
luminal cells of PIN in the absent of gene amplification [23]. Therefore, these studies
suggest a role for MYC overexpression in cancer initiation. Furthermore, the effect of
MYC overexpression has also been examined using MYC transgenic mice.
Overexpression of MYC in the mouse prostate induces formation of PIN followed by
progression to invasive prostate adenocarcinoma [24]. Together, these results indicate
that up-regulation of MYC is a critical oncogenic event associated with prostate cancer
progression.

Loss of PTEN
PTEN was identified as a tumor suppressor gene, and is frequently mutated or
deleted in many cancers, including prostate cancer [25-27]. The chromosomal region on
10q23 where PTEN is located frequently undergoes allelic loss in prostate cancer, which
results in loss of PTEN expression in prostate tumors [28]. Recent studies have found that
loss of PTEN expression is primarily due to bi-allelic deletion in local prostate cancer
[29]. PTEN loss has been observed in 20-30% of locally progressive prostate cancers
specimens [29, 30]. To investigate the role of PTEN loss on prostate cancer development,
genetically engineered mouse models have been generated. Prostate-specific deletion of
PTEN in these mice causes PIN, followed by progression to invasive adenocarcinoma
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[31]. Loss of PTEN in heterozygous mutants or conditional PTEN deletion in the prostate
epithelium also recapitulates many of the events associated with prostate cancer in
humans [32]. Knockout of PTEN in prostate of mice also promotes progression to
castration-resistance [33, 34]. These data indicate that PTEN loss in mice is sufficient to
initiate prostate cancer and demonstrate the importance of PTEN during prostate cancer
progression.

Progression of prostate cancer to castrate-resistance
During the progression of prostate cancer, tumors usually become resistant to
treatments that reduce male hormones, i.e. androgens. The development and progression
of prostate cancer are dependent on the androgens which mediate transcription through
androgen receptor (AR). In prostate tumor cells, binding of androgen to AR forms a
complex that translocates to the nucleus. This complex binds to AR-responsive elements
and controls transcription of androgen-regulated genes [35]. Activation of androgenregulated genes further stimulates cell proliferation and inhibits apoptosis of tumor cells
[35, 36]. This dependence of early stage prostate cancer on androgen stimulation serves
as the basis for androgen-deprivation therapy [37]. Presently, androgen-deprivation
therapy has been widely used by chemical astration to decrease tumor growth [38].
However, patients who have received androgen-deprivation therapy will ultimately
progress after an average of 12 to 18 months, as their tumor adapts to the androgendeprived environment and develops “castrate-resistant” disease [39].
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The mechanism of developing castrate-resistant prostate cancer is not fully
understood. In castrate-resistant prostate cancer (CRPC) cells, the AR can be activated,
and androgen-responsive genes such as PSA [40] continue to be expressed. Several
mechanisms have been proposed for the development of CRPC. First, prostate cancer
cells can upregulate AR expression and become hypersensitive to androgen stimulation
[41], which may occur through selective outgrowth of castration-resistant cells during
castration [42]. Second, the AR may be activated by other steroids such as estrogens or
be activated in a ligand-independent pathway by receptor tyrosine kinases and growth
factors [43-45]. For example, overexpression of HER-2/neu has been shown to activate
AR in CRPC cells [46]. Insulin-like growth factor (IGF) also can bind and activate AR
during castration [42]. Furthermore, Src kinase is critical for bombesin-induced ARmediated activity and is required for translocation and transactivation of AR [45]. In
another mechanism, the production of androgen is upregulated through intratumoral
synthesis by intracrine and paracrine pathways, which also contributes to castrateresistant in CRPC cells [43]. Clearly, multiple mechanisms have been shown to
contribute androgen-independence in CRPA. Currently, new AR antagonists such as
MDV3100 [47] and abiraterone [48] have shown promise results in clinical trials.
However, most patients treated with these AR antagonists ultimately develop resistance
to these agents. More studies for the treatment of CRPC either using AR antagonists
alone or in combination with other agents are urgently warranted.
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Prostate cancer metastasis and microenvironment
Men with CRPC usually develop metastasis in distant organs and progress to
metastatic CRPC. The process of cancer metastasis is very inefficient but highly selective
and dependent on the interaction between tumor cells and the target organs. The classic
model of metastasis of solid tumors, the “seed and soil hypothesis”, was first proposed by
Stephen Paget in 1889 [49]. In Paget’s model, the tumor cells (i.e. seeds) only
metastasize to specific organs (i.e. soil) that are fertile for the tumor growth. This concept,
while remaining a guiding principle for metastasis does not entirely explain the molecular
bases for organ specific metastases. With the accumulation of knowledge from cancer
metastasis studies, metastases of solid tumors including prostate cancer is now known to
involve multiple steps. Metastatic cancer cells undergo a series of processes including
angiogenesis, local migration, invasion, intravasation, circulation, extravasation and
colonization in the distant organs. Thus, cancer cells must alter signaling to gain cell
properties that are critical to ensure successful metastasis.

Moreover, metastasis is not solely dependent on alteration of cancer cell
properties, but also requires bidirectional communication between cells and their
surrounding environment. The tumor microenvironment is comprised of stromal cells
including fibroblasts, endothelial cells, and immune cells, which are recruited to the
tumor. A variety of growth factors, cytokines, chemokines and extracellular matrix (ECM)
proteins secreted by stromal cells can promote growth of tumor cells and increase their
metastatic potential [50, 51]. In contrast, tumor cells also interact with stromal cells to
change their properties in favor of tumor growth. Therefore, interaction between tumor
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cells and the stromal compartment is critical to promote cancer progression and
metastasis [52]. Most of these intercellular interactions are dependent on cell adhesion
molecules (CAMs) and receptors on the cell surface including cadherin and integrins.
Various mechanisms of alteration in these molecules have been shown to promote
metastasis, including reducing cell-matrix adhesion, increasing migratory ability,
surviving in circulation, and colonization in the distant organs [53], which will be
discussed below.

Epithelial plasticity
In the normal prostate gland, basal cells in the lumen attach to the basement
membrane, forming a cell layer underneath normal epithelial cells. Adhesions of
epithelial cells to each other and to ECM restrict the migratory capability of epithelial
cells [54]. In the initial stage of metastasis, tumor cells have to detach from substratum
and migrate from the primary tumor into the surrounding blood or lymphatic vessels. The
adhesions of cell-cell and cell-matrix are mediated by forming of intercellular junctions
that are composed of protein complexes with CAMs. Therefore, tumor cells must
decrease the adhesiveness by altering the expression of different CAMs. For example,
expression of most integrins and E-cadherin are decreased in primary prostate tumors [55,
56]. This process is a major feature of epithelial to mesenchymal transition (EMT), which
allows cells to acquire a more mesenchymal phenotype, increasing their abilities to
migrate and invade the ECM [57]. However, in the distant sites, cancer cells reverse this
process for mesenchymal to epithelial transition (MET) to thereby regaining an epithelial
phenotype allowing adherence to ECM and growth at the metastatic site. This ability of
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cancer cells to switch between different phenotypes through EMT and MET is a feature
of “epithelial plasticity” [58, 59].

Survival in circulation
The metastatic process is not efficient because most disseminated cancer cells are
rapidly destroyed in the circulation. Studies have demonstrated that cancer cells are
frequently released from the tumor into the circulation [60]; but only less than 0.1% of
these disseminated cancer cells can survive and metastasize [61]. Thus, survival of
prostate cancer cells in the circulation is one of the rate-limiting steps in cancer
metastasis [62]. Normally, epithelial cells require attachment to the ECM through
integrin signaling for survival and growth. Disruption of cell-ECM interaction results in
loss of attachment, which impairs integrin-mediated survival signaling and induces
apoptosis, a process termed anoikis [63]. Thus, anoikis prevents disseminated normal
epithelial cells from colonizing at inappropriate locations. For prostate cancer cells to
metastasize in the bone, dislodged cells have to survive in the circulation before
colonizing the bone [64]. Therefore, metastatic tumor cells must acquire the ability to
survive in the circulation. Constitutive integrin signaling is one of the mechanisms by
which prostate cancer cells develop anoikis resistance. In metastatic prostate cancer cells,
integrin signaling is often increased leading to activation of downstream FAK/Src and
Akt pathways, promoting cell survival in circulation [65, 66].
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Development of bone metastasis
Currently, studies of prostate cancer bone metastasis have focused on the
bidirectional interactions of bone microenvironment and prostate cancer cells. In the bone
microenvironment, surviving prostate cancer cells have to attach to capillary endothelial
cells or sub-endothelial basement membranes and then extravasate and grow in the bone
to complete the process of metastasis. These later steps in prostate cancer metastasis are
the most poorly understood, but are specific to the bone compartment. For example,
prostate cancer cells have a higher affinity to bind human bone marrow endothelial
(HBME) cells than they bind to other endothelial cells [67]. Thus, bone metastasis likely
requires interaction of prostate cancer cells with bone microenvironment for metastasis to
develop.

The bone matrix is composed of 95% of type I collagen and 5% of remaining
non-collagen proteins and proteoglycans [68]. Type I collagen, as well as non-collagen
matrix proteins such as osteopontin, bone sialoprotein and osteonectin, serve as ECM
molecules that abet attachment of prostate cancer cells in the bone [69, 70]. Many of
these bone matrix proteins are ligands of integrins, and have been implicated in
facilitating colonization of prostate cancer cells in the bone [71]. The cells in the bone
marrow include osteoblasts (for bone formation), osteoclasts (for bone resorption),
hematopoietic cells, adipocytes and immune cells. Osteoblasts are derived from
mesenchymal stem cells in the bone marrow stroma and differentiate to osteocytes when
embedded in the bone [72]. The newly formed bone matrix will be hardened by
mineralization with deposition of hydroxyapatite crystals to increase resistance to
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compression [68]. Differentiated osteoblasts secrete many growth factors, and some of
those are embedded in the bone matrix. During bone resorption, osteoclasts secrete acids
and proteases to resorb bone and also release these growth factors from bone matrix,
which stimulate prostate cancer cells growth in bone [52, 73, 74]. In contrast, secreted
factors from prostate cancer cells also stimulate proliferation and maturation of
osteoblasts and osteoclasts that, in turn, produce or release even more growth factors and
further stimulate metastatic growth of tumor in the bone. This interaction between
prostate cancer cells and osteoblasts/osteoclasts and other cells in the bone
microenvironment is commonly termed the “vicious cycle” in which tumor growth
affects bone remodeling and bone remodeling contributes to tumor growth [52, 74, 75].
Therefore, the bidirectional interactions between bone cells and prostate cancer cells
highlight the importance of the bone microenvironment in promoting bone metastasis.
Despite the complexity of the bone microenvironment and the experimental difficulty in
understanding mechanisms by which prostate cancer cells home to bone, many adhesion
molecules have been shown to promote prostate cancer bone metastasis. Among them,
cadherin-11 is involved in the metastasis of prostate cancer cells to bone [76, 77].
Treatment of anti-cadherin-11 antibody mAb 2C7 effectively prevented metastasis of
PC3-MM2 cells to bone in vivo [78]. Integrin α2β1 has been shown to increase migration
and adhesion of cancer cells on collagen, and to promote prostate tumor growth in bone
[79, 80].
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Therapy resistance
Resistance to therapies is a recurrent problem in prostate cancer bone metastasis.
However, the molecular understanding of the mechanisms of resistance is still limited.
When disseminated tumor cells colonize distant organs, a small population of tumor cells
may enter a quiescent phase and become dormant for years [62, 81, 82]. Unfortunately,
most therapies target actively proliferating cells, and thus these quiescent tumor cells are
likely to be resistant to the therapies and persist [83]. Eventually, these cells will escape
from dormancy and grow leading to metastasis. Although the mechanism of breaking
dormancy is unknown, the interaction of microenvironment and tumor cells may be
responsible for dormancy and recurrence. Studies have shown that β1 integrin activation
is a key regulator to switch dormancy to proliferation and tumor recurrence when
supplementation of ECM proteins activates integrin signaling [84]. In breast cancer cells
resistant to multiple antitumor drugs, β1 integrin expression was decreased, which
correlates drug resistance [85]. These findings suggest that reduced expression of β1
integrins may be important in cancer cell dormancy and resistance to drug treatment.
However, in proliferating cells, β1 integrin signaling is increased, leading to activation of
the PI3K/Akt survival pathway. This signaling leads to resistance to cytotoxic
chemotherapies in breast cancer cells [86]. In addition, β1 integrin expression was also
increased upon exposure to ionizing radiation [87]. Therefore, these studies suggest that
β1 integrins play an important role in therapy resistance through multiple mechanisms.
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Integrins: structure, activation and signaling
While numerous alterations in tumor cells are associated with integrins, aberrant
integrin expression or activation has been shown to be involved in nearly every step of
cancer metastasis. Thus, I focus on studying the role of integrins in prostate cancer
metastasis in this dissertation.

Structure of integrins
Integrins belong to a family of adhesion molecules consisting of 18 α and 8 β
subunits that comprise 24 glycoprotein heterodimers [88, 89]. Integrins bind specific
ligands in the ECM and promote diverse processes such as adhesion, migration, survival
and proliferation [88, 89]. Although the precise structure for each integrin heterodimer
has not been resolved, a study of the X-ray crystal structure of integrin αvβ3 provides a
model for integrin structure (Figure 1) [90]. Based on this model, the α and β subunits of
integrins form an extracellular “headpiece” that is connected by a short transmembrane
domain to a cytoplasmic tail. The headpiece of the integrin heterodimer is composed of a
βA-domain in the β subunit and a β-propeller domain in the α subunit [91]. The βAdomain is linked to the hybrid domain that acts as a lever, and the angle between the two
domains controls ligand binding affinity. Therefore, the affinity of integrins to ligands is
tightly regulated by the conformational changes of individual integrin heterodimers [92].
Integrins exist in three principal conformations with different affinities for ligands: an
inactivated, “bent” conformation (low affinity), a partially activated, “extended”
conformation with a closed headpiece (high affinity), and a “fully” activated
conformation with an open headpiece (ligand occupied) [90].
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Figure 1. Integrin domain structures. Integrins are heterodimers consisting of an α and
a β subunit. The inactive integrins are in a bent conformation (see the figure; left), and
can be unfolded once activated (see the figure; right). The N-terminal domains of α and β
subunit interact and form a headpiece that provides a ligand binding site. The C-terminal
domains of each subunit form two legs with transmembrane domains and cytoplasmic
tails.

From Shattil SJ, Kim C, Ginsberg MH (2010) The final steps of integrin activation: the
end game. Nat Rev Mol Cell Biol 11: 288-300. Reproduced with permission.
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Activation of integrins
Integrins can be activated by binding ligands or interacting with intracellular
proteins. Activation of integrins is regulated by bidirectional cellular signaling illustrated
in Figure 2 [91]. Traditionally, binding of ECM ligands induces a conformational change
leading to activation of integrins. Such activation is generally termed “outside-in”
activation, which results in conformational changes leading to opening the hinge between
the βA- and hybrid domains in the integrin headpiece as described above [93, 94]. In
addition to ligands, other factors can also affect outside-in integrin activation. For
example, Mg2+ and Mn2+ can activate and stabilize a high affinity conformation of
integrins, while Ca2+ has an inhibitory effect and stabilizes a low affinity conformation
[95]. Although inactive integrins can be activated by ligand binding, the affinity of
inactive integrins to ligands is much lower than that of activated integrins. Hence,
another mechanism to activate integrins and increase binding affinity is through binding
intracellular proteins.

Cellular signaling can promote intracellular proteins, such as talins, to bind
integrins, which induces conformational changes in integrins leading to their activation.
This direction of integrin activation, through intracellular signaling, is usually termed
“inside-out” activation. Generally, the two directions of integrin activation stimulate
signaling pathways that have different biological consequences in cells. Inside-out
signaling is responsible for cell adhesion and controls interactions with ECM proteins,
and therefore regulates cell migration and ECM assembly. Outside-in signaling through
ECM ligand binding leads to transition of intracellular signaling, which controls cell
polarity, survival, proliferation, cytoskeletal structure and gene expression [91].
- 16 -

Figure 2. “Outside-in” and “inside-out” integrin signaling. There are two directions
of integrin signaling. In “outside-in” signaling, integrins work as traditional receptors in
binding ligands and transmitting signals into the cells (left figure), while in “inside-out”
signaling, intracellular proteins, such as talin, bind to the integrin tail and induce a
conformational change leading to activation of integrins (right figure). Molecules
involved in these procedures are shown in the figure.

From Shattil SJ, Kim C, Ginsberg MH (2010) The final steps of integrin activation: the
end game. Nat Rev Mol Cell Biol 11: 288-300. Reproduced with permission.

- 17 -

However, the two mechanisms of integrin activation are not mutually exclusive, nor
independently regulated. For example, inside-out activation of integrin can increase
integrin affinity for ligands. This process in turn promotes ligand binding of integrins
resulting in outside-in activation. Following activation, integrins bind variety of ligands
including collagens, laminins, or RGD-containing proteins (such as fibronectin) [96].
Certain integrin α subunits only pair with specific β subunits to form heterodimers and
thus create specificity as to which ligands bind which integrins (Figure 3). For the 24
different heterodimers, 12 of them contain β1 subunits and only these pairing with α1, α2,
α10 and α11 can bind to collagens, the major component of bone (Figure 3). Thus, β1
integrins are likely to play an important role in prostate cancer bone metastasis.

Integrin signaling
Integrins have no intrinsic enzymatic activity; thus, their transmission of signaling
relies on integrin-associated effectors. Activation of integrins leads to recruitment of
focal adhesion kinase (FAK) to their cytoplasmic tails. When integrins cluster, the
integrin tails will be brought together, which leads to FAK interaction and autophosphorylation of FAK on Y397. Subsequently, Src family kinase and PI3K bind to
pFAK Y397 and together induce phosphorylation of other focal adhesion components
including paxillin and p130 CAS to initiate signaling [97]. Activation of FAK/Src
through phosphorylation is known to activate additional signal pathways including
mitogen-activated protein kinases (MAPKs) and PI3K/Akt [98]. Integrin activation
induces phosphorylation of p21 activated kinase (PAK) that activates MAPK pathway
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Figure 3. Integrin subunits and their ligands. Ligands for leukocyte integrins include
E-cadherin, fibrinogen, factor X, intercellular adhesion molecule, inactive complement
factor 3b, vascular cell adhesion molecule, and von Willebrand Factor. RGD-containing
ligands include bone sialoprotein, fibronectin, latency-associated-peptide of transforming
growth factor β1/3, nephronectin, osteopontin, thrombospondin, and vitronectin.

From Margadant C, Monsuur HN, Norman JC, Sonnenberg A (2011) Mechanisms of
integrin activation and trafficking. Curr Opin Cell Biol 23: 607-614. Reproduced with
permission.
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through activating Raf. Another major result of integrin activation is stimulation of the
PI3K/Akt signaling pathway. PI3K catalyzes PIP2 to PIP3 that recruits and activates
other proteins, including the Akt kinase. While PTEN is frequently lost in prostate cancer
leading to activation of the PI3K pathway, integrin-mediated activation of PI3K/Akt has
also been shown to promote cancer cell migration and survival [99]. Studies showed that
osteopontin, an ECM protein in bone, increases cell migration and adhesion through
PI3K/Akt pathway in PC3 cells [100]. β1 integrins also increase the expression of
survivin through the Akt pathway, which protects prostate cancer cells from apoptosis
induced by the TNF-α [101]. In addition, integrins α5β1 and αvβ3 (but not αvβ1), protect
cells from apoptosis by increasing Bcl-2 expression via FAK and PI3K pathways [102,
103].

β1 integrins in prostate cancer
In normal prostate glands, the basal cells express integrins that bind beneath the
basement membrane. However, during the progression of prostate cancer, these basal
cells are usually lost, and integrin expression is altered. Most α and β subunit expression
is downregulated, whereas only α2, αIIb, α6, β1, β3 and β6 are upregulated [55]. Among
these upregulated integrins, only α2, α6, β3 and β6 subunits have been shown to be
overexpressed in metastases [55], but their roles in metastasis are unknown. In prostate
cancer cells, β1 integrins contain five different alternatively spliced variants, β1A, β1B,
β1C, β1C-2, and β1D [104]. Among the five known β1 integrin cytoplasmic variants,
β1A integrins are ubiquitously expressed, whereas β1C levels are reduced in neoplastic
prostate epithelium [105]. In addition, prostate cancer cell lines, including PC3, LNCaP
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and DU145, mainly express β1A integrins that increase cell proliferation, whereas the
β1C variant (not expressed in prostate cancer cells) acted as an inhibitor of proliferation
[106].

Expression of β1 integrins has been shown to increase migration and invasion.
Several β1 integrins are associated with increased metastasis in prostate cancer, including
α5β1and α2β1 [79, 107, 108]. Trerotola et. al. showed that α5β1 integrins increase
migration of prostate cancer cells by associating with talin and relocalizing from focal
adhesions to the leading edges of cells [108]. In addition to migration, β1 integrins also
form a complex with IGF-IR to promote proliferation of prostate cancer cells in 3D
cultures [109]. Studies demonstrated that α5β1 integrins on prostate cancer cells interact
with bone stroma, suggesting that they may play a critical role in tumor growth in the
bone. Blocking α5β1 integrins by monoclonal antibodies inhibits adhesion of DU-145
prostate cancer cells to bone marrow stromal cells [107, 110]. Another β1 integrin family
protein, α2β1, has been shown to increase migration and adhesion of cancer cells on
collagen, and promotes prostate tumor growth in the bone [79, 80]. Similar to α5β1, α2β1
was found to mediate adhesion of malignant tumor-derived prostate epithelial cells to
human bone marrow stroma, which can also be inhibited by antibodies targeting α2β1
[111].

Little is known about the role of β1 integrin activation in promoting prostate
cancer metastasis. Very recently, Dr. Sue-Hwa Lin and collaborators have demonstrated
that β1 integrins are constitutively activated in prostate cancer cell lines with high
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metastatic potential, but not in cancer cell lines with low metastatic potential [112]. Dr.
Lin and collaborators also showed that blocking β1 integrins using a specific anti-β1
integrin antibody (33B6) inhibits adhesion, migration, survival and integrin signaling in
prostate cancer cells [112]. Furthermore, treatment of mAb 33B6 by intraprostatic
injection suppressed metastasis of PC3-MM2 from the prostate to distant lymph nodes in
a spontaneous metastasis mouse model. In an experimental metastasis mouse model
following intracardiac injection, blocking β1 integrins by systemic delivery of mAb 33B6
suppressed metastasis of PC3-MM2 cells to bone (Figure 4) [112]. Thus, these studies
demonstrated the importance of β1 integrin activation in prostate cancer bone metastasis,
and that blocking β1 integrin activation inhibits bone metastasis. Therefore, I focused on
studying the role of β1 integrin activation in prostate cancer bone metastasis in my
dissertation. Furthermore, I addressed how β1 integrin activation promotes prostate
cancer bone metastasis and hypothesized that talin may have a unique role in β1 integrin
activation that promotes metastasis of prostate cancer cells.

Talin in inside-out integrin activation
Talin is essential to activate integrins by directly binding to the cytoplasmic tail of
the β subunit. Although several integrin-associated proteins have been shown to facilitate
integrin activation including kindlin and ILK, only talin can directly bind integrins and is
sufficient to activate integrins [113]. Overexpression of talin has been observed in several
solid tumors, including prostate cancer [114], oral squamous cell carcinoma [115] and
ovarian serous carcinoma [116], and generally overexpression correlates with higher
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A

B

Figure 4. Inhibition of PC3-MM2 cells metastasis in vivo by anti-β1 integrin
antibody mAb 33B6. (A) Inhibition of PC3-MM2 metastasis to lymph node in vivo by
mAb 33B6. Luciferase-labeled PC3-MM2 cells were injected into the prostate of SCID
mice. Mice were treated with IgG or mAb 33B6 (1 mg/kg) before tumor cell inoculation
and twice a week subsequently by intraperitoneal injection. Bioluminescence imaging of
mice was conducted weekly afterwards to monitor tumor growth and metastasis in vivo.
Average numbers of lymph node ± SD metastases detected at the termination of the study.
(B) Inhibition of disseminated PC3-MM2 cell metastasis in bone by mAb 33B6. Tumor
burden in the femurs of the control and mAb 33B6-treated mice. Luciferase-labeled PC3MM2 cells were injected into the left ventricle of SCID mice. Mice were treated with IgG
or mAb 33B6 (1 mg/kg) before tumor cell inoculation and twice a week subsequently by
intraperitoneal injection. Bioluminescence imaging was acquired as above setting. P <
0.05.

From Lee YC*, Jin JK*, Cheng CJ*, Huang CF, Song JH, Huang M, Brown WS, Zhang
S, Yu-Lee LY, Yeh ET, McIntyre BW, Logothetis CJ, Gallick GE, Lin SH (2013)
Targeting constitutively activated beta1 integrins inhibits prostate cancer metastasis. Mol
Cancer Res 11: 405-417. *shared first authorship. Reproduced with permission.
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tumor grade and metastasis [114-116]. However, little is known about the role of talin in
cancer. Studies have shown that knockdown of talin reduces cell migration in ovarian
serous carcinoma cells [116]. Overexpression of a dominant-negative form of talin, talin
L325R, significantly reduces cell proliferation and increases apoptosis in oral squamous
cells [115]. In prostate cancer, talin knockdown decreases cell adhesion, migration and
invasion, while overexpression of talin increases anoikis resistance through focal
adhesion signaling [114]. However, the role of talin in cancer metastasis and the
mechanisms by which talin promotes cancer cell properties were unknown, prior to my
work. I hypothesize talin’s role in tumorigenesis occurs through activating β1 integrins,
which is a major topic of this dissertation.

Structure of talin
Two distinct talin genes (TLN1 and TLN2, 74% sequence identity) are expressed
in vertebrates, with talin1 expressed in nearly every tissue and talin2 normally expressed
primarily in the heart, brain, testis and muscles [117-119]. Talins are 270-kDa adaptor
proteins that are localized in adhesion complexes between cells and the ECM, where they
interact with the β integrin cytoplasmic tail and the actin cytoskeleton [120]. Structurally,
talin (including talin1 and talin2) consists of an N-terminal 47-kDa head domain and a
220-kDa C-terminal flexible rod domain (Figure 5) [113, 121]. The talin head consists of
an atypical FERM domain including three subdomains (F1, F2, and F3) and a F0
subdomain [122]. The talin head contains binding sites for β integrin tails [123, 124], Factin [125], phosphatidylinositol 4-phosphate 5-kinase γ (PIPK1γ) [126] and acidic
phospholipids such as phosphatidylinositol-4,5-bisphosphate (PIP2) [127]. The talin head
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Figure 5. Domain structure of talin. Talin is composed of three major domains: FERM
(head), linker and rod domain. The FERM domain includes F1, F2 and F3 subdomains.
The rod domain includes multiple actin and vinculin binding sites. The Ser425
phosphorylation site in the linker domain is indicated by a red star.

From Bate N, Gingras AR, Bachir A, Horwitz R, Ye F, Patel B, Goult BT, Critchley DR
(2012) Talin contains a C-terminal calpain2 cleavage site important in focal adhesion
dynamics. PLoS One 7: e34461. Reproduced with permission.
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and rod are linked via residues 401-481 amino acid, which contains a calpain cleavage
site at 432 amino acid [128]. The talin rod domain is composed of a series of helical
bundles that contain multiple actin-binding sites, vinculin binding sites and a second
integrin-binding site [129]. Therefore, talin functions as an adaptor protein, as it
conjugates integrins to the cytoskeleton [129], and further promotes integrin-mediated
signal transduction.

Talin-mediated inside-out integrin activation
Major insights into the principal function of talin were derived from experiments
demonstrating that the talin head binds the cytoplasmic tails of β integrin subunits leading
to the final step in inside-out integrin activation [124, 130]. The major integrin-binding
site at the talin head is located within the F3 subdomain containing a phosphotyrosinebinding (PTB) domain, which interacts with the membrane-proximal NPxY motif in the
cytoplasmic tails of the β integrins [131, 132]. Crystallographic data revealed that talinmediated integrin activation is dependent on binding of the talin F3 subdomain to the β
integrin tail in two steps. First, the talin head interacts with the β integrin tail by binding
the NPxY motif through its PTB domain (Figure 6). Second, the loop region on the talin
F3 subdomain subsequently interacts with the membrane-proximal region within the β
integrin tail to displace the integrin tail. The displacement of the integrin tail results in
separating the two legs of integrin α/β subunits thereby inducing a conformational change
from an inactive bent structure to an extended conformation [122] (Figure 6). Integrins in
this ‘primed’, extended form, are activated with their extracellular domains extended and
the ligand-binding site exposed, which increases the binding affinity to specific ECM
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Figure 6. Talin-mediated integrin activation. (A) Inactive talin can be activated by
binding of PIP2, calpain cleavage and possibly through phosphorylation (described in this
dissertation) to release the autoinhibitory conformation. (B) During integrin activation,
the F3 subdomain on the talin head binds the membrane proximal NPXY motif of β
integrin tail. (C) The talin loop structure in the head interacts with the membraneproximal α helix of the β integrin cytoplasmic tail and separates the connection between
integrin α/β tails.

From Moser M, Legate KR, Zent R, Fassler R (2009) The tail of integrins, talin, and
kindlins. Science 324: 895-899. Reprinted with permission from AAAS.
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proteins. Ligand binding induces full activation and clustering of integrins. The talin
bound with integrin tails then recruits vinculin, FAK, actin and other focal adhesion
proteins to form a focal adhesion complex that conjugates integrins with the cytoskeleton
(Figure 7).
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Figure 7. Talin-mediated integrin activation and subsequent focal adhesion
formation. (A) In the inactive state, integrins are in a bent conformation. (B) Binding of
talin in the cytoplasmic tail of integrins promotes to a partially activated extended
conformation with increased affinity to ECM. (C) Ligand-bound integrins are in a fully
activated state. In the cytoplasm, several focal adhesion proteins such as FAK, Src,
vinculin and paxillin are recruited to talin for assembly of focal adhesion complexes.

Modified from Legate KR, Montanez E, Kudlacek O, Fassler R (2006) ILK, PINCH and
parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 7: 20-31. Reproduced with
permission.
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Because integrin activation has to be strictly regulated in normal cells, binding of
talin to integrin is tightly controlled. In the cytoplasm, talin forms an antiparallel dimer
via a single helix in the C-terminal rod [133]. In this autoinhibitory conformation, the Cterminal talin rod binds the N-terminal PTB domain, which blocks the integrin binding
pocket [134]. Therefore, talin itself must be activated prior to binding integrins. How
talin is activated is not clear, but the mechanism must involve disruption of autoinhibitory
conformation. Several mechanisms have been proposed to relieve this inhibitory
conformation, including binding PIP2 [135, 136], calpain cleavage [137] and talin
phosphorylation [138]. PIP2 is a known to activate talin by inducing conformational
changes [135]. Studies of the talin crystal structure revealed that PIP2 on the plasma
membrane attracts the positively charged talin head and simultaneously repels the
negatively charged talin rod [136]. Such a “pull-push” process relieves the autoinhibitory
conformation. In the calpain cleavage model, talin is cleaved by calpain at amino acid
432, yielding an N-terminal 50-kDa globular head domain and a 220-kDa C-terminal rod
domain [137]. Thus, the N-terminal head cleaved product can bind to integrin with the
FERM domain and is sufficient to activate integrins.

Talin phosphorylation
In addition to the above described mechanisms, phosphorylation of talin has been
proposed to induce an active conformation. Hence, in the phosphorylated residues in talin
have been mapped using mass spectrometry. Talin is heavily phosphorylated on 30 sites
including, serine, threonine and tyrosine residues [139]. Most of the sites are predicted to
be phosphorylated by PKA, PKC and cyclin-dependent kinase 5 (Cdk5). Although the
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functions of these phosphorylated sites are unknown, talin phosphorylation has been
implicated in regulation of membrane-cytoskeleton interactions [140-142]. One of the
most heavily phosphorylated sites is on talin1 serine 425, which resides in the talin linker
domain [143]. Phosphorylation of talin on S425 was shown to inhibit binding to Smurf1
and prevents talin head ubiquitylation and degradation [143]. Mutation of talin S425 to
inhibit phosphorylation results in decreasing cell migration in neural cells [143]. Because
talin S425 phosphorylation regulates cell properties associated with integrin functions,
talin phosphorylation may plausibly regulate integrin activation. Structurally,
phosphorylation of proteins can induce a conformational change [144]; therefore, talin
phosphorylation could be one of the possible mechanisms to relieve the inhibitory
conformation and lead to talin activation, thus promoting integrin binding and integrin
activation. However, the potential role of talin phosphorylation in integrin binding and
integrin-mediated signalings has not been assessed previously.

Cdk5 in talin phosphorylation
Studies of Huang et. al. have shown that talin is phosphorylated on S425 by Cdk5
in normal cells [143]. Cdk5 belongs to a member of the cyclin-dependent kinase family
of proline-directed protein kinases. Cdk5 was originally isolated from screening of Cdk1
and is 58% and 62% sequence identical with Cdk1 and Cdk2, respectively [145].
Although Cdk5 was cloned as a homologue to other Cdk family proteins, Cdk5 is mostly
expressed in terminally differentiated neurons of developing nervous system [146], and
regulates the migration of post-mitotic neurons during embryogenesis [147], thus is not
involved in cell cycle regulation. However, the mechanisms by which Cdk5 regulates
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neuronal migration in the embryonic and adult brains are still unknown. One possible
mechanism is through altering microtubule dynamics by phosphorylating proteins that are
critical for nucleokinesis, such as Nudel1, FAK and PAK [148-151]. Cdk5 is activated by
two non-cyclin regulatory subunits, p35 and p39 [152, 153]. While p39 is specifically
expressed in the cerebellum, p35 is expressed in various tissues, including prostate [154156]. p35 does not show homology with other known cyclins and does not activate other
members of Cdk family [152]. Thus, p35 has high specificity for Cdk5 activation [152].
In addition to their roles in neurons, several studies have shown that Cdk5 is activated in
non-neuronal cells, including pancreatic cells [157] and corneal epithelial cells [158]. In
prostate cancer, Cdk5 and its activator p35 are highly expressed in primary tumors and
metastases compared with normal tissues [155, 156]. Cdk5 was shown activated in
prostate cancer cells, Strock et. al. demonstrated that overexpression of dominantnegative Cdk5 in prostate cancer cells inhibits lung metastasis in xenograft mice [156].
These results suggest that Cdk5 activity promotes prostate cancer metastasis. Intriguingly,
Cdk5 has also been shown to increase migration and cell-matrix adhesion, i.e. functions
associated with β1 integrin activation [158, 159]. Recently, a study showed that Cdk5 and
p35 are clustered with talin and β1 integrins into lamellipodia during cell spreading [160].
Inhibition of Cdk5 activity using the pan-Cdk inhibitor, roscovitine, prevents binding of
talin/integrin, which suggests that Cdk5 activation may be involved in integrin activation.
Thus, Cdk5 and p35 may play important roles in talin phosphorylation-mediated integrin
activation, which will be studied in this dissertation.
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Summary of the problem and hypothesis
Prostate cancer is the most commonly diagnosed cancer in men in the western
world with a nearly 29,500 deaths anticipated in 2014 in the United States [1, 161].
Although patients with organ-confined prostate cancer are usually successfully treated,
for those with metastases, the 5-year survival decreases to 28% [1]. Prostate cancer has a
high propensity for metastasizing to the bone. Thus, understanding the mechanisms by
which prostate cancer cells metastasize to the bone will be critical for designing novel
therapeutic strategies for metastasis prevention.

Recent studies have implicated β1 integrin signaling in promoting critical steps in
prostate cancer metastasis, such as adhesion, migration, invasion and cellular survival.
Several β1 integrins on prostate cancer cells have been shown to interact with bone
matrix and promote tumor growth in the bone [79, 80, 111]. However, the role of β1
integrins in prostate cancer bone metastasis remains unknown. A better understanding of
the β1 integrin signaling pathway by which prostate cancer cells increase metastatic
potential is needed. Moreover, the mechanism by which β1 integrins are activated in
prostate cancer cells is also unknown. Although, talin has been shown to regulate integrin
activation and thus is a candidate for activating β1 integrins in prostate cancer cells, the
potential role of its phosphorylation in β1 integrin activation has not been assessed
previously. In addition, talin, Cdk5 and p35 have been implicated in prostate cancer
metastasis, but whether they are in a signaling axis that promotes β1 integrin activation
leading to bone metastasis was not clear prior to my studies.
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The goal of this Ph.D. dissertation work was to investigate the roles of talin1
phosphorylation in prostate cancer metastasis and specifically to understand the
mechanism of talin1 phosphorylation in activating β1 integrins and the effects in
promoting prostate cancer bone metastasis. Therefore, the first question addressed in the
dissertation work was whether β1 integrins are activated through inside-out β1 integrin
activation in metastatic prostate cancer cells, and what would be the effects to cancer
cells. The second question was whether talin1 phosphorylation promotes β1 integrin
activation in metastatic prostate cancer cells, and what would be the effects of talin
phosphorylation on cancer cells? The third question was what is the mechanism by which
talin1 is phosphorylated in prostate cancer cells? The fourth question was whether talin1
phosphorylation promotes prostate cancer bone metastasis in vivo.

The hypothesis tested in this dissertation was that β1 integrins are constitutively
activated in metastatic prostate cancer cells through talin1 S425 phosphorylation, which
is required to promote prostate cancer metastasis. To test this hypothesis, I first
determined the correlation of β1 integrin activation with metastatic potential of cancer
cells, and whether β1 integrins were activated through inside-out signaling. Then, I
investigated whether talin phosphorylation promotes β1 integrin activation in prostate
cancer cells by talin silencing and mutation, and examined the effects of talin
phosphorylation on integrin associated functions in cancer cells. For the third question, I
determined the potential mechanism that increased p35 expression promotes Cdk5
activity that phosphorylates talin resulting in β1 integrin activation in prostate cancer
cells. Finally, I assessed the effects of talin phosphorylation in prostate cancer metastasis
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in vivo and investigated the clinical relevance of talin phosphorylation in prostate cancer
tissues. Together, this work addressed the mechanism and biological function of talin
phosphorylation and provides a better understanding of the mechanism for prostate
cancer metastasis.
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Chapter 2
Materials and Methods
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This chapter is based upon “Lee YC*, Jin JK*, Cheng CJ*, Huang CF, Song JH,
Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, McIntyre BW, Logothetis CJ,
Gallick GE, Lin SH (2013) Targeting constitutively activated beta1 integrins inhibits
prostate cancer metastasis. Mol Cancer Res 11: 405-417” with permission from AACR,
*shared first authorship, and based upon “Jin JK, Tien PC, Cheng CJ, Song JH, Huang C,
Lin SH, Gallick GE (2014) Talin1 phosphorylation activates β1 integrins: a novel
mechanism to promote prostate cancer bone metastasis. Oncogene (in press)” with
permission.

Cell lines and culture condition
The PC3 and PC3-MM2 cells were gifts from Dr. Isaiah J. Fidler at the M. D.
Anderson Cancer Center. The PC3-MM2 is a highly metastatic cell line derived
following two passages of PC3-M cells in nude mice of selecting and re-passaging lymph
node metastases [162]. LNCaP cells were obtained from the American Type Culture
Collection. The C4-2B4 cells were gifts from Dr. Sue-Hwa Lin at the M. D. Anderson
Cancer Center. The C4-2B4 cells derived from bone metastasis are a C4-2 subline
derived from LNCaP [163]. These cell lines as well as those that were gene-silenced or
engineered to express talin1 mutants were maintained in RPMI-1640 medium
supplemented with 10% fetal bovine serum. To increase cell attachment, β1 integrin
knockdown, talin1 knockdown and talin1S425A expressing cells were cultured on poly-Dlysine (Sigma, St. Louis, MO) coated plates. Cell lines were checked every six months
and found to be mycoplasma free, and the identity of cell lines was authenticated at the M.
D. Anderson Cell Identification Core Facility.
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Antibodies
Anti-talin1 (97H6) antibody was purchased from GeneTex (San Antonio, TX).
Anti-pan total talin (8d4) and β-actin antibodies were purchased from Sigma. Anti-ptalin
S425 antibody and blocking peptide were purchased from ECM Biosciences (Versailles,
KY). Anti-active β1 integrin (9EG7) and total β1 integrin (MAR4, 18) antibodies were
purchased from BD Biosciences (San Jose, CA). Anti-active β1 integrin (12G10) and
talin2 (68E7) antibodies were purchased from Abcam (Cambridge, MA). Anti-Cdk5 (C-8)
and p35 (C-19) antibodies were purchased from Santa Cruz (Dallas, TX). Anti-FAK,
PARP, cleaved PARP, AKT, pAKT S473, p130 Cas, pp130 Cas Y165, GFP and Myc-tag
antibodies were purchased from Cell Signaling (Danvers, MA). Anti-pFAK Y397 and
Alexa Fluor 647-conjugated secondary antibodies were purchased from Life
Technologies (Grand Island, NY).

Flow cytometric analysis of β1 integrins
Cultured cells (1 × 105) were detached by trypsin without EDTA, resuspended in
0.5 ml of ice-cold PBS buffer with 0.5% bovine serum albumin (BSA; Sigma Cat. no.
A7030) and 0.04% sodium azide, and incubated on ice for 10 min. Anti-active β1 integrin
(9EG7; 1:300), active β1 integrin (12G10; 1:300), total β1 integrin (MAR4; 1:300)
antibodies or isotype IgG control were added and incubated on a rocker for 1 hr at 4 ℃.
Cells were centrifuged at 500 ×g for 5 min, washed with PBS three times, and then
incubated with Alexa Fluor 647-conjugated secondary antibody (1:500) in 1 ml of PBS
with 0.5% BSA on a rocker for 30 min at 4 ℃ in the dark. Labeled cells were washed
twice with PBS and subjected to FACS analysis using a FACS Canto II flow cytometer
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(BD Biosciences). Labeled cells were fixed and subjected to FACS analysis within one
week. To fix cells, labeled cells were washed with PBS and resuspended in 1%
paraformaldehyde for 5 min followed by washing with PBS containing 0.5% BSA and
stored at 4 ℃ in the dark. Expression of activated and total β1 integrins was quantitated
by geometric mean fluorescence intensity using FlowJo software (Tree Star, Ashland,
OR).

Immunoblotting
Cells were washed with PBS and lysed with RIPA buffer (10 mM Sodium
phosphate, pH 7.2, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholic acid, 2 mM EDTA, 1%
Triton X-100, 10% glycerol, protease inhibitor cocktail, and PhosSTOP phosphatase
inhibitor cocktail; Roche, Indianapolis, IN). Cell lysates were sonicated (Bioruptor XL,
Diagenode, Denville, NJ) for 90 sec on ice and centrifuged at 14,000 ×g for 20 min at 4
℃. Protein concentration of the supernatants was measured using a DC protein assay kit
(Bio-Rad, Hercules, CA). The supernatants (30 µg) were mixed with Laemmli sample
buffer, boiled for 5 min, and subjected to SDS-PAGE. Proteins were transferred on
PVDF membranes followed by blocking with 5% milk for 1 hr. For phospho-protein
immunoblotting, membranes were blocked in 5% BSA for 2 hr. Membranes were
incubated with primary antibodies for 1 hr at room temperature, or overnight at 4 ℃.
Then, horseradish peroxidase-conjugated secondary antibodies (1:6500) were incubated
with membrane for 1 hr. Membranes were incubated with SuperSignal Femto Substrate
(Thermo) and exposed to X-ray films to detect proteins.
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Immunofluorescence staining
Cells were cultured on coverglasses (Grace Bio-Labs, Bend, OR) for 18 hr, fixed
in 4% paraformaldehyde for 15 min, washed with PBS, permeabilized with 0.1% Triton
X-100 in PBS for 10 min, and incubated in blocking buffer (LI-COR, Lincoln, NE) for 1
hr. Antibodies (anti-active β1 integrin 12G10, 1:100; anti-total β1 integrin clone 18,
1:100) were diluted in blocking buffer and incubated for 18 hr at 4 ℃. Slides were
washed with PBS and incubated with Alexa Fluor 647-conjugated secondary antibody for
1 hr. Nuclei were stained using Hoechst 33342 (Life Technologies). Slides were treated
with ProLong Gold antifade Reagent (Life Technologies) and images were acquired
using a TCS SP5 confocal microscope (Leica, Buffalo Grove, IL) and analyzed using
Image-Pro Plus software (Media Cybernetics, Rockville, MD). For fluorescence area
quantitation, a threshold of fluorescence intensity was used to define fluorescence area on
images. The number of pixels in the area with an intensity above the threshold was
counted and normalized to cell count for each image.

Anoikis assays
Cells (1 × 106) were detached by trypsin, resuspended in 13 ml of serum-free
medium containing 0.05% BSA in a 15 ml conical tube with vent cap, and rotated in an
incubator to prevent cell aggregation. For counting live and dead cells, 500 µl of cell
suspension was incubated with 2 mM Calcein AM (BD Biosciences) for 30 min at 37 ℃
followed with 4 mM propidium iodide (BD Biosciences) and counted under a
fluorescence microscope. For cells expressing talin mutants, live cells were counted by
trypan blue exclusion using a Vi-Cell XR cell viability analyzer (Beckman Coulter,
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Indianapolis, IN). The cells in the cell suspension were centrifuged at 500 ×g for 5 min
and lysed in RIPA buffer at specific times followed by immunoblotting for PARP and
cleaved PARP. To detect apoptotic cells using propidium iodide FACS analysis, the cell
suspension was centrifuged, fixed by resuspended in ice-cold 70% ethanol and incubated
at 4 ℃ for overnight (see appendix for protocol). Cells were centrifuged and washed with
PBS and resuspended in 50 µl of PBS with 2 mg/ml ribonuclease A and incubated for 5
min on ice. PBS (450 µl) containing 75 µM propidium iodide was added and incubated
for 30 minutes on ice followed by analyzing using FACS analysis. Cells in the subG0/G1 were quantitated using FlowJo software.

Lentivirus-mediated gene silencing
To decrease β1 integrin expression, a viral pLKO.1-puro plasmid (Sigma)
containing a shRNA sequence 5’-GCCCTCCAGATGACATAGAAA-3’ was used. Two
plasmids containing different shRNA sequences were used to decrease talin1 or talin2
expression. sh-Talin1 sequences used were 5’-CCCAGAGTATTAACGCTCCAA-3’
targeting UTR region, and 5’-GCCTCAGATAATCTGGTGAAA-3’ targeting CDS
region. sh-Talin2 sequences used were 5’-GACGAATCCAAACACGAAATC-3’ and 5’ACGATGCGTGTCGAGTCATTC-3’. To decrease Cdk5 expression, the sequence used
was 5’-CAGAACCTTCTGAAGTGTAAC-3’. A non-targeting shRNA sequence 5’GCGCGATAGCGCTAATAATTT-3’ in the same vector was used as a sh-control
plasmid. For lentivirus production, the pLKO.1-puro plasmid (3 µg) was co-transfected
with the packaging plasmid pCMV-dR8.2 dvpr (3 µg) and the envelope plasmid pCMVVSV-G (0.6 µg) in a ration of 5:5:1 into 293FT cells in one 100-mm plate (Life
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Technologies) using Lipofectamine 2000 (Life Technologies). After 24 hr, medium was
replaced with 20% FBS. The viral supernatant was collected after 24 h and again at 48 hr,
filtered through 0.45 µm filters followed by centrifugation at 20,000 rpm for 2 hr at 4 ℃.
The viral pellet was resuspended in 200 µl of RPMI medium and stored at -80 ℃. Cells
cultured in 48-well plates were incubated with 20 µl of virus supernatant in the present of
8 µg/ml of polybrene (Sigma) and centrifuged at 500 ×g for 20 min and further incubated
for 24 hr. The medium was changed after 24 h and replaced again with 5 µg/ml
puromycin after 48 hr and incubated for one week to select stable silenced cells. For
Cdk5 knockdown, cells were tranduced and lysed after 48 hrs without selection.

Immunoprecipitation
Cells were lysed in lysis buffer containing 50 mM Hepes, pH 7.4, 150 mM NaCl,
1% Triton X-100, 0.1% SDS, 1% deoxycholic acid, 10% glycerol, protease inhibitor
cocktail, and phosphatase inhibitor cocktail. Lysates (500 µg protein) were diluted twofold in immunoprecipitation buffer (50 mM Hepes, pH 7.4, 150 mM NaCl, 0.1% Triton
X-100, and 10% glycerol) and incubated with anti-talin1 (97H6) antibody (5 µg) plus 5
µM cytochalasin D for 3 h at 4 ℃. Protein G-coupled agarose beads (50 µl) were added
into the mixture and incubated for 1 h at 4 ℃ followed by washing using lysis buffer once
and immunoprecipitation buffer three times, and immunoblotting were subjected.

Mutagenesis
To express talin1WT and mutants in prostate cancer cells, human full-length talin1
cDNA in pEZ-M29-talin1 plasmid was purchased from GeneCopoeia (Rockville, MD).

- 42 -

To generate pWPXL-GFP-talin1WT, full-length talin1 DNA fragments were amplified by
PCR using pEZ-M29-talin1 as a template and
5’GCTGTACAAGTCCGGCATGGTTGCACTTTCACTGAAGA3’ (primer #1) and
5’GAGATCTGAGTCCGGACAAGAAAGCTGGGTTGCG3’ (primer #2; see appendix
for subcloning protocol). The DNA fragments were subcloned into BspEI partial-digested
pWPXL-GFP vector (gift of Dr. Didier Trono, Addgene plasmid #12257) using InFusion HD cloning system (Clontech, Mountain View, CA) according to the
manufacturer’s instructions (see appendix for plasmid maps). To generate pWPXL-GFPtalin1S425A, the pEZ-M29-talin1 was used as a template for PCR amplification and
5’GACTCAGTGGCCCCCAAAAAGTCAACAGTCCTG3’ and
5’GGGCCACTGAGTCCTCCAGCATAGTAGACTCCTC3’ (underline denotes mutated
site) as complementary mutagenic primers to generate linearized pEZ-M29-talin1S425A,
and then recircularized using the In-Fusion system (see appendix for mutagenesis
protocol). The pEZ-M29-talin1S425A was then used as the template for PCR amplification
with primer #1 and #2 to generate full-length talin1 1-2542S425A DNA fragments, which
were inserted into a BspEI partial-digested pWPXL-GFP vector using In-Fusion enzyme.
The same procedures above were used to generate pWPXL-GFP-talin1S425D with the
following complementary mutagenic primers:
5’GACTCAGTGGACCCCAAAAAGTCAACAGTCCTG3’ and
5’GGTCCACTGAGTCCTCCAGCATAGTAGACTCCTC3’ for PCR amplification.
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Transfection
To generate stable GFP-talin1WT and mutant cells, pWPXL-GFP-talin1WT, mutant
plasmids and pWPXL-GFP (empty vector) were transiently transfected into talin1silenced cells using jetPRIME (Polyplus-transfection, Illkirch, France) according to the
manufacturer’s instructions. For talin1 knockdown in PC3-MM2 and C4-2B4 cells, a
pLKO plasmid directing expression of shRNA to the talin1 UTR was used, therefore not
interfering with expression of GFP-talin1 mutant proteins subsequently expressed.
Transient transfected GFP-talin1 mutant cells were sorted for GFP positive cells by a
flow cytometer at the M. D. Anderson Flow Cytometry and Cellular Imaging Core
Facility to select stable transfected cells with similar levels of GFP expression. For Cdk5
overexpression, plasmids of empty vector (pEF4-myc-His), Cdk5 wild-type (pEF4-mycHis-Cdk5), and dominant-negative Cdk5 (pEF4-myc-His-Cdk5-144N) [143] were
transiently transfected using jetPRIME.

Proliferation assays
Cells (5 × 104) were cultured on 60-mm CellBind plates (Corning) in triplicate for
specific times. Cells were detached by trypsin and live cell number were counted by
trypan blue exclusion using a Vi-Cell XR cell viability analyzer.

Adhesion assays
Tissue culture treated 96-well plates were coated with fibronectin (5 µg/cm2; BD
Biosciences), or collagen I (5 µg/cm2; BD Biosciences) for 1 hr at 37 ℃, then blocked by
1% BSA. Cells were detached by trypsin without EDTA, resuspended in serum-free
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medium and incubated in plates at 4 × 104 cells per well in triplicate for 5 min at 37 ℃.
Plates were washed three times by 100 µl of PBS to remove unattached cells. Attached
cells were incubated with 1 µM Calcein AM (BD Biosciences) in PBS for 5 min at 37℃.
Fluorescence-labeled cells were lysed in 100 µl of 1% Triton X-100, and the fluorescence
intensity was measured using an Envision plate reader (PerkinElmer, Waltham, MA).

Migration and invasion assays
Migration assays were performed using collagen I coated (1 µg/cm2)
polycarbonate transwell filters in 24-well plates (8-µm pore size; Corning, Tewksbury,
MA). For invasion assays, Matrigel coated filters (BD Biosciences) were used. Cultured
cells were detached by trypsin, suspended in serum-free medium and incubated in the
upper chamber of transwell inserts at a density of 5 × 104 cells per well. The medium in
the bottom chamber was supplemented with 0.1% FBS as a chemoattractant. Cells were
allowed to migrate for 8 hr or to invade for 24 hr. Cells adhering to the bottom of the
filters were stained with HEMA 3 stain kit (Fisher Scientific, Kalamazoo, MI) and then
the cells on the upper side of the filter were removed by cotton tips. Images of filters
were acquired at 20× using a microscope with camera (Eclipse Ti-S; Nikon, Melville,
NY). Cell numbers on images were counted using Image-Pro Plus software.

Cdk5 kinase activity assays
Cdk5 kinase activity was measured using ADP-Glo kinase assay (Promega,
Madison, WI) according to the manufacturer’s instructions. Cells were lysed in a buffer
containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5%
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deoxycholic acid, 5 mM EDTA, protease inhibitor cocktail, and phosphatase inhibitor
cocktail. Cell lysate (500 µg) was incubated with anti-Cdk5 antibody (5 µg) in modified
lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% deoxycholic acid, 1 mM
DTT, 1 mM EDTA, 1 mM EGTA, protease inhibitor cocktail, and phosphatase inhibitor
cocktail) for 1 h at 4 ℃ followed by incubated with 50 µl of protein A-coupled agarose
beads for 3 h at 4 ℃. The agarose beads were washed using modified lysis buffer and
resuspended in 10 µl kinase reaction buffer (40 mM Tris-HCl, pH 7.5, 20 mM MgCl2 and
0.1 µg/µl BSA). Cdk5 enzyme reaction was initiated by incubating agarose beads in
kinase reaction buffer for 30 min at 30 ℃ with 170 µM histone H1 peptide
PKTPKKAKKL (Enzo Life Sciences, Farmingdale, NY) and 50 µM ATP in a final
volume of 25 µl. ADP produced during kinase reaction was measured using ADP-Glo
kinase assay according to the manufacturer’s instructions (see appendix for protocol).
The reaction mixture (20 µl) was transferred to a 384-well plate, and luminescence read
using an Envision plate reader.

In vivo metastasis assays
PC3-MM2 sh-control, talin1-silenced with GFP, GFP-talin1WT and GFP-talin1
mutant cells were transduced with lentivirus containing a plasmid directing luciferase
expression (pLenti-PGK-Blast-V5-LUC [164], i.e. the Addgene plasmid #19166) as
described above, and then incubated with 5 µg/ml blasticidin to select stable transduced
cells. All animal studies were reviewed and approved by the Institutional Animal Care
and Use Committee (IACUC) guidelines of M. D. Anderson Cancer Center. For
intracardiac injection (experimental metastasis assays), the cells (1 × 106) were suspended
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in 50 µl of PBS and injected into left ventricle of male nude mice. Bioluminescence
images were acquired immediately after intracardiac injection to proper ensure
distribution of cells in mice, and then were used to monitor tumor growth. For
bioluminescence imaging, mice were injected intraperitoneally with 100 µl of 15 mg/ml
luciferin in PBS, imaging using a Xenogen IVIS 200 system (PerkinElmer) was
performed 10 min later. X-ray and matched bioluminescence images were acquired and
superimposed using a Kodak In-Vivo Multispectral Imaging System FX (Carestream,
Rochester, NY). For intraprostatic injections (spontaneous metastasis assays), the
procedure of Kim et al. [165] was followed. Male athymic nude mice (NCr-nu/nu; ages
8–12 wk) were anesthetized placed in a supine position. A midline incision was made on
the lower abdomen, and the prostate was exteriorized. Cells (5 × 105) in 10 µl of PBS
were injected into the dorsolateral side of the prostate. The incision was closed with
surgical metal clips. The growth of primary tumor was monitored by bioluminescence
imaging. Mice with similar sized primary tumors were sacrificed, primary tumors were
removed and the lymph node metastases were identified by bioluminescence imaging.

Immunohistochemistry
Human prostate cancer tissue samples from primary tumor, lymph node
metastases and bone metastases were obtained from the prostate cancer tissue bank at M.
D. Anderson Cancer Center, under an approved IRB protocol. To validate the specificity
of anti-ptalin S425 antibody, PC3-MM2 cells were fixed in 10% formalin, pelleted and
embedded in agarose (see appendix for protocol). Sections of agarose cell blocks were
incubated with ptalin S425 antibody alone or simultaneously with corresponding
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blocking peptide (ECM Biosciences) followed by using the same procedures in tissue
staining. For tissue staining, formalin-fixed, paraffin-embedded sections in 4-µm-thick
were de-waxed with xylene, rehydrated in graded concentrations of alcohol followed by
heat-induced epitope retrieval at 121 ℃ for 10 min in citrate buffer (pH 6.0) using a
pressure cooker. Tissue sections were treated with 3% hydrogen peroxide for 30 min,
washed with PBS, blocked with 5% normal horse serum for 30 min, and incubated at 4 ℃
overnight with anti-ptalin S425 antibody. Antibody binding was detected using biotinstreptavidin system (Vector Laboratories, Burlingame, CA) with 3,3’-diaminobenzidine
as the chromogen. Hematoxylin was used as the counterstain. The immunostaining
results were reviewed and scored by pathologists as described previously [112]. Tissues
were defined as positive when over 10% of cells were stained.

Statistical analyses
Data are shown as means ± s.d. One-way ANOVA and post Tukey’s test were
used to determine significance in metastasis assays. A chi-square test was used to
evaluate immunohistochemical analysis. Other assays were determined by two-tailed
Student’s t-test. P-values less than 0.05 were considered statistically significant.
Statistical analyses were conducted using GraphPad Prism software (GraphPad Software,
La Jolla, CA).
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Chapter 3
Constitutive activation of β1 integrins in metastatic prostate
cancer cells
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This chapter is based in partly upon “Lee YC*, Jin JK*, Cheng CJ*, Huang CF,
Song JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, McIntyre BW,
Logothetis CJ, Gallick GE, Lin SH (2013) Targeting constitutively activated beta1
integrins inhibits prostate cancer metastasis. Mol Cancer Res 11: 405-417” with
permission from AACR, *shared first authorship, and based in partly upon “Jin JK, Tien
PC, Cheng CJ, Song JH, Huang C, Lin SH, Gallick GE (2014) Talin1 phosphorylation
activates β1 integrins: a novel mechanism to promote prostate cancer bone metastasis.
Oncogene (in press)” with permission.

Activation of β1 integrins correlates with metastatic potential of prostate cancer
cells
To examine whether activation of β1 integrins plays a role in prostate cancer
metastasis, I determined β1 integrin expression and activation in several available
prostate cancer cell lines, including the lymph node-derived LNCaP and its variant C42B4, as well as the PC3 and its metastatic variant PC3-MM2 cells. LNCaP and C4-2B4
cells are tumorigenic, however, with low metastatic potential when implanted
orthotopically or intracardially. PC3 and PC3-MM2 are tumorigenic and highly
metastatic, exhibiting high incidence of metastasis in both spontaneous and experimental
bone metastasis models [77, 166]. Using anti-total β1 integrin mAb MAR4, FACS
analysis showed that all 4 cell lines expressed high levels of β1 integrins (Figure 8). Next,
we examined integrin activation in these cell lines. Western blot showed that the levels of
phosphorylation of pFAK Y397 are higher in PC3 and PC3-MM2 than LNCaP and C42B4 cells (Figure 9), suggesting that integrin signaling is in a more activated state in PC3
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Figure 8. FACS analysis of total β1 integrins in prostate cancer cell lines. (A) FACS
analysis using anti-total β1 integrin antibody, mAb MAR4. Cells incubated with
secondary antibody only were used as negative controls. (B) Quantitation of geometric
mean fluorescence intensity of total β1 integrins.
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Figure 9. Immunoblotting of cell lysates for the expression of FAK and
phosphorylated FAK Y397. (A) Immunoblotting of pFAK Y397 and total FAK using
cell lysates from prostate cancer cells. (B) Quantitation of band intensity in
immunoblotting.
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and PC3-MM2 cells with higher metastatic potential. We further used the conformationsensitive antibody 9EG7 to examine whether β1 integrins in these cells were present in
the activated conformation. Monoclonal antibody 9EG7 recognizes the EGF-like repeats
1-4 that were exposed in activated β1 integrins [167-169]. The data showed that 9EG7
binds to PC3 and PC3-MM2 strongly (Figure 10). In contrast, 9EG7 showed only modest
binding to LNCaP and C4-2B4 (Figure 10). β1 integrin activation was further examined
by immunofluorescence staining using another conformation-specific antibody, mAb
12G10, that binds to exposed βA domain during β1 integrin activation [170, 171].
Activation of β1 integrins, determined by fluorescence area, was 20-fold higher in
metastatic PC3-MM2 cells as compared to low metastatic C4-2B4 cells (Figure 11).
These observations suggest that β1 integrins are present in an activated conformation
only in cell lines with high metastatic potential.

- 53 -

A

B

Figure 10. FACS analysis of activated β1 integrins in prostate cancer cell lines. (A)
FACS analysis using a conformation-sensitive antibody, mAb 9EG7, targeting activated
β1 integrins. Cells incubated with secondary antibody only were used as controls. (B)
Quantitation of geometric mean fluorescence intensity of activated β1 integrins.
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Figure 11. Immunofluorescence staining of activated and total β1 integrins. (A) PC3MM2 and C4-2B4 cells were stained using a conformation-sensitive antibody for
activated β1 integrins (mAb 12G10) and total β1 integrins (mAb 18; bottom panels).
Nuclei were counterstained by Hoechst 33342. Scale bar represents 25 µm. (B)
Differences in expression by quantitating pixels of immunofluorescence area. *PC3MM2 compared to C4-2B4, P < 0.05. **PC3-MM2 compared to C4-2B4, P < 0.001.
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β1 integrin activation correlates with anoikis resistance in prostate cancer cells
Integrin signaling is critical to increase cell survival [172]. Thus, I examined
whether increased β1 integrin activation in metastatic prostate cancer cells correlated
with cell survival by using an anoikis assay. Single cells from prostate cancer cell lines
were placed in suspension with serum-free medium and constantly rotated for 24 and 48
hours to prevent aggregation-induced outside to inside integrin aggregation. The number
of viable and dead cells was then determined. As shown in Figure 12, PC3-MM2 has the
highest number of viable cells at 48 hours, whereas LNCaP and C4-2B4 cells did not
survive in these anoikis conditions. The decreases in viable cell number corresponded to
the increases in dead cell number (Figure 12). Analysis of nuclear integrity by FACS of
propidium iodide staining showed that the increased dead cell number in anoikissensitive cell lines correlated with an increase in the sub-G1 fractions (Figure 13),
suggesting that these cells had undergone apoptosis. Consistent with this result, western
blot analysis showed a correlation between anoikis sensitivity and increases in PARP
cleavage (Figure 14). These observations indicate that the ability of prostate cancer cells
to survive in anoikis conditions correlates with the activation status of β1 integrins and
also the metastatic potential of these cell lines.
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Figure 12. Viable and dead cell number of prostate cancer cells in anoikis
conditions. Cells were grown in anoikis condition as described in Materials and Methods.
(A) Viable and (B) dead cell numbers were determined by Calcein AM and propidium
iodide staining under a microscope, respectively.
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Figure 13. FACS analysis of propidium iodide-labeled apoptotic cells. (A) Cells were
grown in anoikis conditions for 24 and 48 hr. Cell counts of propidium iodide-labeled
cells after 24 hr suspension. Percentage indicated apoptotic cell population in sub-G1. (B)
Quantitation of apoptotic cells in sub-G1.
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Figure 14. Immunoblotting of PARP and cleaved PARP. PC3 or PC3-MM2 cells
grown under anoikis conditions for various lengths of times. Cells were lysed and
subjected to immunoblotting.
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Silencing of β1 integrins in PC3-MM2 cells by expression of shRNA abrogates
anoikis resistance
To examine the causal effect of β1 integrin signaling on prostate cancer cell
survival, I used stable expression of shRNA to knockdown β1 integrins in PC3-MM2
cells. As shown in Figure 15, transfection of β1 integrin-specific shRNA reduced the
expression of β1 integrins by more than 90%, whereas control non-targeting shRNA did
not have significant effects on β1 integrin expression. To examine the effects on integrinmediated survival pathways, phosphorylation of FAK Y397 and AKT S473 were
examined. Knockdown of integrin greatly reduced pFAK Y397 and pAKT S473
phosphorylation (Figure 15). Furthermore, the β1 integrin knockdown cells in suspension
were sensitized to anoikis (Figure 16), with a concomitant increase in PARP cleavage
(Figure 17). These results suggest that β1 integrin signaling plays a critical role in the
survival of highly metastatic PC3-MM2 cells.
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Figure 15. Immunoblotting of β1 integrins, pFAK Y397, total FAK, pAkt S473, and
total Akt in β1 integrin knockdown cells. A stable PC3-MM2 cell line was derived in
which β1 integrins are reduced by expression of shRNA as described in Materials and
Methods.
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Figure 16. Viable cell number of β1 knockdown PC3-MM2 cells in anoikis
conditions. Control and β1 knockdown PC3-MM2 cells were grown in anoikis
conditions for 24 and 48 hr as described in Materials and Methods. Viable cell numbers
were determined by Calcein AM staining.
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Figure 17. Immunoblotting of PARP and cleaved PARP in β1 integrin knockdown
cells in anoikis conditions. β1 integrin knockdown PC3-MM2 cells were cultured under
anoikis conditions for indicated times. Cell lysates were used for immunoblotting for
PARP and cleaved PARP.
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Chapter 4
Talin1 phosphorylation regulates β1 integrin activation
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This chapter is based in partly upon “Jin JK, Tien PC, Cheng CJ, Song JH,
Huang C, Lin SH, Gallick GE (2014) Talin1 phosphorylation activates β1 integrins: a
novel mechanism to promote prostate cancer bone metastasis. Oncogene (in press)” with
permission.

Talin1, but not talin2, activates β1 integrins in prostate cancer cells
Talin is required for inside-out integrin activation and is overexpressed in prostate
cancer [114]. Therefore, I determined whether talin expression contributes to constitutive
β1 integrin activation in metastatic prostate cancer cells. Because talins are expressed
from two genes, TLN1 and TLN2, I first compared the effect of talin1 and talin2 in β1
integrin activation by gene silencing in PC3-MM2 cells. Silencing of talin1 did not affect
the expression of talin2 (Figure 18). While both talin1 and talin2 are expressed in PC3MM2 cells, talin1 is far more abundant as total talin detected by the pan-talin antibody,
8D4, was significantly reduced in talin1-silenced cells (Figure 18). In addition, talin1silenced cells possessed a rounded morphology and impaired spreading (Figure 19), a
phenotype not observed in talin2-silenced cells (Figure 19, 20). Next, the levels of total
and activated β1 integrins in talin1 and talin2-silenced PC3-MM2 cells were determined.
Flow cytometric analysis demonstrated that silencing of talin1 (Figure 21), but not talin2
(Figure 22), reduced β1 integrin activation, without affecting expression of total β1
integrins. These results demonstrate that talin1, but not talin2, was primarily responsible
for β1 integrin activation in prostate cancer cells.
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Figure 18. Immunoblotting of talin1, talin2 and pan-talin in talin1-silenced cells.
Silencing of talin1 in PC3-MM2 cells by shRNA expression using two sequences as
described in Materials and Methods. A non-targeting shRNA sequence in the same vector
was used as an sh-control.
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Figure 19. Effects of talin1 and talin2 silencing on cell spreading. Morphology of
talin1- and talin2-silenced PC3-MM2 cells were observed using a light microscope. Scale
bar represents 100 µm.
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Figure 20. Immunoblotting of talin2 and talin1 in talin2-silenced cells. Silencing of
talin2 in PC3-MM2 cells by shRNA expression using two sequences as described in
Materials and Methods.
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Figure 21. Flow cytometric analysis of activated β1 integrins and total β1 integrins
in talin1-silenced PC3-MM2 cells. FACS analysis using conformation-sensitive
antibodies for activated β1 integrins and for total β1 integrins (top panels). Relative
expression of activated and total β1 integrins quantitated by fluorescence intensity is
shown in the bottom panels. *sh-Talin1 compared to sh-control, P < 0.005.
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Figure 22. Flow cytometric analysis of total β1 integrins and activated β1 integrins
in talin2-silenced PC3-MM2 cells. FACS analysis using conformation-sensitive
antibodies for activated β1 integrins and for total β1 integrins (top panels). Relative
expression of activated and total β1 integrins quantitated by fluorescence intensity is
shown in the bottom panels.
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Talin1 S425 phosphorylation correlates with activated β1 integrins in PC3-MM2
cells
Talin1 has been shown to increase metastatic properties associated with β1
integrin functions in prostate cancer cells [114]. Therefore, I determined whether talin1
expression correlates with β1 integrin activation. I collaborated with the laboratory of Dr.
Sue-Hwa Lin to examine talin1 expression in low metastatic LNCaP, C4-2B4, metastatic
PC3 and PC3-MM2 cells. The level of talin1 expression was similar in each cell line
(Figure 23). These results suggest that increased talin1 expression alone is insufficient to
activate β1 integrins. Since talin phosphorylation on S425 is also associated with some
integrin functions such as migration [143], we next examined talin1 and talin2
phosphorylation on S425 by immunoblotting. Talin (comprising talin1 and talin2) was
highly phosphorylated on S425 in metastatic PC3 and PC3-MM2 cells compared to low
metastatic LNCaP and C4-2B4 cells (Figure 23). To examine talin1 phosphorylation
specifically, cell lysates were immunoprecipitated with a talin1-specific antibody,
followed by immunoblotting with an antibody recognizes talin S425 phosphorylation.
Talin1 was highly phosphorylated in PC3 and PC3-MM2 cells (Figure 24), consistent
with immunoblotting observed from whole cell lysates (Figure 23). These results
demonstrate that levels of talin1 S425 phosphorylation correlate with activated β1
integrins in PC3-MM2 cells.
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Figure 23. Talin1 expression and talin S425 phosphorylation in prostate cancer cells.
(A) Immunoblotting of total talin1 and talin S425 phosphorylation using whole cell
lysates from prostate cancer cells. (B) Quantitation of band intensity from
immunoblotting.
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Figure 24. Phosphorylation of talin1 on S425 in prostate cancer cells. (A)
Immunoprecipitation of talin1 followed by immunoblotting of talin S425 phosphorylation
in indicated prostate cancer cells. (B) Quantitation of band intensity from immunoblotting.
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Talin1 S425 phosphorylation promotes β1 integrin activation
To determine if talin1 S425 phosphorylation were required for β1 integrin
activation, I silenced endogenous talin1 and stably expressed either talin1 wild-type
(GFP-talin1WT), a non-phosphorylatable mutant (GFP-talin1S425A), or a phosphorylationmimicking mutant (GFP-talin1S425D) in PC3-MM2 and C4-2B4 cells as described in
Materials and Methods. Levels of expression of each form of talin1 were similar (Figure
25). Flow cytometric analysis demonstrated that talin1WT expressed in talin1-silenced
PC3-MM2 cells restored β1 integrin activation (Figure 26). In contrast, expression of
talin1S425A inhibited β1 integrin activation by 60%, whereas talin1S425D promoted β1
integrin activation by 76% relative to talin1WT. Similar results were observed when
talin1WT and mutants were expressed in C4-2B4 cells in which endogenous talin1 was
silenced (Figure 27). I further assessed the effects of talin1 phosphorylation on β1
integrin activation by immunofluorescence staining. In agreement with the flow
cytometric analysis, fewer activated β1 integrins were expressed in talin1S425A cells
relative to talin1WT cells, while talin1S425D cells showed increased clustering of active β1
integrins (Figure 28). Next, I examined whether talin1 phosphorylation affects
downstream integrin signaling. The PC3-MM2 talin1S425A cells were decreased in
expression of pFAK Y397, pp130 Cas Y165 and pAkt S473 but not total FAK, p130 Cas
or Akt (Figure 29), consistent with decreased signaling through activated β1 integrins.
Similarly, in talin1-silenced cells, pFAK Y397, pp130 Cas Y165 and pAkt S473 were
decreased with no decrease in expression of these proteins; whereas in cells re-transfected
with talin1WT, activation of these downstream intermediates was restored. Together, these
results demonstrate that talin1 S425 phosphorylation promotes β1 integrin activation and
downstream signaling in metastatic prostate cancer cells.
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Figure 25. Expression of talin1 mutants in prostate cancer cells. (A) Expression of
GFP (empty vector), GFP-talin1WT and specified GFP-tagged talin1 mutants in talin1silenced PC3-MM2 and (B) in talin1-silenced C4-2B4 cells.
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Figure 26. Flow cytometric analysis of activated and total β1 integrins of PC3-MM2
talin1 mutants. PC3-MM2 cells expressing talin1WT and mutants were subjected to flow
cytometric analysis using antibodies for activated β1 integrins (9EG7) and total β1
integrins (MAR4; top panels). Quantitation of fluorescence intensity is shown in the
bottom panels. The sh-talin1 knockdown cells were served as a negative control. *P <
0.005.
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Figure 27. Flow cytometric analysis of activated and total β1 integrins of C4-2B4
talin1 mutants. C4-2B4 cells expressing talin1WT and mutants were subjected to flow
cytometric analysis using antibodies for activated β1 integrins (9EG7) and total β1
integrins (MAR4; top panels). Quantitation of fluorescence intensity is shown in the
bottom panels. The sh-talin1 knockdown cells served as a negative control. *P < 0.005.
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Figure 28. Immunofluorescence staining of GFP and activated β1 integrins.
Immunofluorescence staining of GFP and activated β1 integrins (using mAb 12G10) in
PC3-MM2 cells expressing talin1WT and mutants. Nuclei were counterstained by Hoechst
33342. Scale bar represents 25 µm.
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Figure 29. Effect of talin1 phosphorylation on activation of downstream β1 integrin
signaling. Immunoblotting of pFAK Y397, total FAK, pp130 Cas Y165, total p130 Cas,
pAkt S473 and total Akt in PC3-MM2 cells expressing talin1WT and talin1 mutants. The
sh-talin1 knockdown cells served as a negative control.
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Chapter 5
Effects of talin1 phosphorylation in prostate cancer cells
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This chapter is based in partly upon “Jin JK, Tien PC, Cheng CJ, Song JH, Huang C,
Lin SH, Gallick GE (2014) Talin1 phosphorylation activates β1 integrins: a novel mechanism
to promote prostate cancer bone metastasis. Oncogene (in press)” with permission.

Effects of talin1 S425 phosphorylation on β1 integrin-mediated proliferation and
anoikis resistance
To determine the effect of talin1 S425 phosphorylation on biologic properties of
prostate cancer cells, I used the PC3-MM2 and C4-2B4 cells described above expressing
talin1WT and mutants. Expression of talin1WT, integrin-activating and -inhibiting talin1
mutant proteins had no affect on proliferation rates of PC3-MM2 cells or C4-2B4 cells
(Figure 30). However, when cultured in anoikis conditions, 30% of the nonphosphorylatable talin1S425A-expressing cells died after 24 hr and 40% after 48 hr (Figure
31). In contrast, no cell death was observed in both talin1WT and talin1S425D cells after 24
hr. After 48 h, 35% talin1WT cells died, similar to talin1S425A, but only 16% talin1S425D
died (Figure 31). To determine if effects on viability were due to changes in apoptosis,
propidium iodide staining was performed. A two-fold increase in the sub-G0/G1
population was observed in talin1S425A cells compared to talin1WT cells after 24 hr (Figure
32). After 48 hr, the sub-G0/G1 population in talin1WT cells and talin1S425A cells was
similar, while talin1S425D cells were still resistant to anoikis (Figure 32). As a second
measure of apoptosis, PARP cleavage was examined. PARP cleavage occurred in
talin1S425A cells by 24 hr, but no PARP cleavage was observed in talin1S425D cells even
after 48 hr (Figure 33). Thus, increased anoikis resistance correlated with talin1 S425
phosphorylation in prostate cancer cells.
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B

Figure 30. Effects of talin1 S425 phosphorylation on cell proliferation. (A) PC3MM2 and (B) C4-2B4 cells expressing talin1WT and mutants were plated (5 × 104 cells)
and cultured for indicated times, and then the trypan blue negative cells were enumerated.
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Figure 31. Cell viability of PC3-MM2 cells expressing talin1 mutants in anoikis
conditions. PC3-MM2 talin1WT and mutant-expressing cells were cultured in anoikis
conditions as described in Materials and Methods. Surviving cells were counted at
indicated times. *Talin1WT compared to talin1S425D, P < 0.05.
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Figure 32. Flow cytometric analysis of propidium iodide-labeled cells in sub-G0/G1.
PC3-MM2 talin1WT and mutant-expressing cells maintained in anoikis conditions were
harvested at indicated times and stained with propidium iodide, then were subjected to
FACS analysis. The percentage of cells in sub-G0/G1 is plotted. *P < 0.005.
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Figure 33. Immunoblotting of total and cleaved PARP of talin1 mutants in anoikis
conditions. Immunoblotting of total and cleaved PARP using lysates of PC3-MM2
talin1WT and mutant-expressing cells maintained in anoikis conditions for indicated times.
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Effects of talin1 S425 phosphorylation on β1 integrin-mediated adhesion and
motility
Next, I determined whether talin1 S425 phosphorylation promoted attachment of
metastatic prostate cancer cells to ECM. For these analyses, talin1WT and mutantexpressing cells were subjected to adhesion to fibronectin and collagen I-coated culture
plates. Binding of PC3-MM2 cells expressing talin1S425A to fibronectin was decreased by
74% and to collagen I by 81% relative to talin1WT cells (Figure 34). Binding of PC3MM2 cells expressing talin1S425D to fibronectin was increased by 66% and to collagen I
by 53% relative to talin1WT cells (Figure 34). Very similar results were observed in
adhesion assays when these mutants were expressed in C4-2B4 cells (Figure 35). Next, I
determined whether talin1 phosphorylation promotes motility of prostate cancer cells on
ECM. Migration assays were performed using collagen I-coated modified Boyden
chambers, as described in Materials and methods. The ability of PC3-MM2 cells
expressing talin1S425A to migrate on collagen I was reduced 52% (62% in C4-2B4 cells
expressing talin1S425A) as compared to talin1WT cells, whereas the migratory ability of
talin1S425D-expressing PC3-MM2 cells was increased by 30% (55% in C4-2B4 cells
expressing talin1S425D) relative to respective wild-type transfected cells (Figure 36), again
correlating with the level of β1 integrin activation. Similar results were observed in
invasion assays, in which cells invaded through Matrigel-coated modified Boyden
chambers. The invasive ability of PC3-MM2 cells expressing talin1S425A was reduced
95% (90% in C4-2B4 cells expressing talin1S425A) as compared to talin1WT cells, whereas
the invasive ability of talin1S425D-expressing PC3-MM2 cells was increased by 40% (43%
in C4-2B4 cells expressing talin1S425D) relative to respective wild-type transfected cells
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(Figure 37), demonstrating that talin1 S425 phosphorylation promotes cell migratory and
invasive abilities.
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PC3-MM2

Figure 34. Talin1 S425 phosphorylation promotes cell adhesion in PC3-MM2 cells.
Adhesion of PC3-MM2 talin1WT and mutant-expressing cells on fibronectin and collagen
I-coated plates. Adhesion to BSA served as a negative control. *Talin1WT compared to
talin1S425A, P < 0.005. **Talin1WT compared to talin1S425D, P < 0.0005.
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Figure 35. Talin1 S425 phosphorylation promotes cell adhesion in C4-2B4 cells.
Adhesion of C4-2B4 talin1WT and mutant-expressing cells on fibronectin and collagen Icoated plates. Adhesion to BSA served as a negative control. *P < 0.0005.
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Figure 36. Effect of talin1 S425 phosphorylation on cell migration. (A) PC3-MM2
and (B) C4-2B4 talin1WT and mutant-expressing cells were cultured on collagen I-coated
membranes in modified Boyden chambers. Cells were allowed to migrate through the
membranes for 8 h. *P < 0.0001
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Figure 37. Effect of talin1 S425 phosphorylation on cell invasion. (A) PC3-MM2 and
(B) C4-2B4 talin1WT and mutant-expressing cells were allowed to invade through
Matrigel in modified Boyden chambers for 24 h. *P < 0.0001.
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Chapter 6
Cdk5 regulates talin1 S425 phosphorylation
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This chapter is based in partly upon “Jin JK, Tien PC, Cheng CJ, Song JH, Huang C,
Lin SH, Gallick GE (2014) Talin1 phosphorylation activates β1 integrins: a novel mechanism
to promote prostate cancer bone metastasis. Oncogene (in press)” with permission.

Talin S425 phosphorylation is mediated by Cdk5 which is activated by p35
Previous works in neuronal cells demonstrated that talin phosphorylation on S425
is catalyzed by Cdk5 [143]. To determine the mechanism by which talin1 S425
phosphorylation is increased in metastatic prostate cancer cells, first I examined whether
Cdk5 expression or activity correlated with talin1 phosphorylation in prostate cancer cells.
For these studies, both Cdk5 and p35 expression were determined. Expression of Cdk5
by immunoblotting was similar in LNCaP, C4-2B4, PC3 and PC-3MM2 cells (Figure 38).
However, levels of p35 expression were increased in PC3 and PC3-MM2 cells compared
to LNCaP and C4-2B4 cells (Figure 38). As p35 is known to activate the enzymatic
activity of Cdk5, Cdk5 activity was assessed by ADP production through ADP-Glo
Kinase Assay kit as described in Materials and Methods. Cdk5 activity was increased in
PC3 (2-fold relative to LNCaP) and PC3-MM2 (2.5-fold relative to LNCaP; Figure 39),
which correlated with the increased talin1 phosphorylation and β1 integrin activation in
these cells. To determine whether Cdk5 was responsible for talin1 S425 phosphorylation
in prostate cancer cells, Cdk5 was inhibited in PC3-MM2 cells. Inhibition of Cdk5 by the
non-specific Cdk inhibitor, roscovitine, reduced talin1 phosphorylation in PC3-MM2
cells in a time-dependent manner (Figure 40), suggesting that Cdk5 might be responsible
for talin1 phosphorylation. To examine directly whether Cdk5-mediated talin1
phosphorylation, Cdk5 was silenced in PC3-MM2 and C4-2B4 cells. The results
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Figure 38. Expressions of Cdk5 and p35 in prostate cancer cells. Immunoblotting of
Cdk5 and p35 using cell lysates from different prostate cancer cell lines.
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Figure 39. Cdk5 kinase activity in prostate cancer cells. Cdk5 kinase activity in
prostate cancer cells was measured by ADP production as described in Materials and
Methods. The sh-Cdk5 knockdown cells were used as a negative control. *PC3 compared
to LNCaP cells, P < 0.0005. **PC3-MM2 compared to LNCaP cells, P < 0.0001.
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Figure 40. Talin1 phosphorylation was inhibited by roscovitine. The Cdk inhibitor
Roscoitine (20 µM) was added to PC3-MM2 cells. Cells were incubated and lysed at
indicated times and immunoblotted for talin1 S425 phosphorylation and total talin1.
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demonstrated talin1 phosphorylation was decreased by ~90% (Figure 41). To examine
whether Cdk5 kinase activity was required for talin1 phosphorylation and not functioning
as an adaptor protein, prostate cancer cells were transiently transfected with a plasmid
directing the expression of a dominant-negative Cdk5 [143]. Expression of this dominantnegative mutant inhibited talin1 phosphorylation in both PC3-MM2 and C4-2B4 cells
(Figure 42). These results demonstrated that Cdk5 activity, but not expression, promotes
talin1 S425 phosphorylation in prostate cancer cells. Next I determined whether Cdk5
regulates β1 integrin activation. Silencing Cdk5 resulted in reduced β1 integrin activation
in PC3-MM2 cells (Figure 43), suggesting that Cdk5 is required for β1 integrin activation.
Next, to demonstrate that talin1 phosphorylation was mediated in Cdk5-induced β1
integrin activation, I silenced Cdk5 in PC3-MM2 cells in which talin1 was silenced and
talin1WT or talin1S425D mutants were re-expressed (Figure 44A). As expected, silencing
Cdk5 inhibited β1 integrin activation in talin1WT cells, but did not affect β1 integrin
activation in phospho-mimicking talin1S425D cells (Figure 44B). These observations
demonstrate that Cdk5 phosphorylates talin1 on S425, and its activity promotes β1
integrin activation.
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Figure 41. Immunoblotting of Cdk5, ptalin S425 and total talin1 in Cdk5
knockdown cells. Silencing of Cdk5 in PC3-MM2 or C4-2B4 cells by shRNA
expression was described in Materials and Methods. Cells were infected with lentivirus
and lysed after 48 hr.
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Figure 42. Immunoblotting of ptalin S425, talin1 and Myc-tag in cells expressing
dominant-negative Cdk5. Prostate cancer cells were transfected with Myc-Cdk5 wildtype and dominant-negative fusion construct as described in Materials and Methods, and
talin1 phosphorylation was evaluated by immunoblotting.
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Figure 43. Flow cytometric analysis of Cdk5 knockdown cells. FACS analysis of
activated (9EG7) and total β1 integrins (MAR4) in Cdk5-silenced PC3-MM2 cells (top
panels). Quantitation of fluorescence intensity is shown in the bottom panels. *sh-Cdk5
compared to sh-control, P < 0.0005.
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Figure 44. Talin1 phosphorylation was mediated in Cdk5-induced β1 integrin
activation. (A) Immunoblotting of Cdk5. PC3-MM2 talin1WT and mutant-expressing
cells were transducted with a sh-control vector or a sh-Cdk5 vector to silence Cdk5
expression. (B) Activated (9EG7) and total β1 integrins (MAR4) were measured by
FACS analysis. *P < 0.005.
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Chapter 7
Talin1 phosphorylation promotes prostate cancer bone
metastasis in vivo
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This chapter is based in partly upon “Jin JK, Tien PC, Cheng CJ, Song JH, Huang C,
Lin SH, Gallick GE (2014) Talin1 phosphorylation activates β1 integrins: a novel mechanism
to promote prostate cancer bone metastasis. Oncogene (in press)” with permission.

Talin1 S425 phosphorylation is required for prostate cancer bone metastasis
To determine whether talin S425 phosphorylation promoted metastasis in vivo, I
used two nude mouse models, one of which examined experimental metastasis, and the
other, spontaneous metastasis. For these experiments, the sh-control, talin1-silenced,
talin1 wild-type and mutated talin1-expressing PC3-MM2 cells were transduced with a
vector directing luciferase expression. To determine bone metastasis of disseminated
prostate cancer cells, intracardiac injections were performed (experimental metastasis).
Following intracardiac injection of cells, bioluminescence imaging of mice was
performed weekly. The presence of tumor in bone was examined by co-localization of Xray and bioluminescence imaging. A representative image of mice inoculated with cells
expressing each construct is shown in Figure 45. No tumor growth observed in any
animal in the bone of talin1-silenced and talin1S425A groups. In contrast, 3 of 4 talin1WT
mice and 4 of 5 talin1S425D mice demonstrated tumor growth. Tumors were noted in both
legs of mice as expected in this model as well as in the heads of mice as previously
observed [112, 173] (Figure 46). Thus, blocking talin1 S425 phosphorylation completely
inhibited bone metastasis of disseminated PC3-MM2 cells in this model. For tumors that
grew, tumor size was estimated by bioluminescence imaging 7, 14 and 21 days postintracardiac injection. Exponential growth was observed in sh-control, talin1WT and
talin1S425D groups, with no difference in talin1WT and talin1S425D observed (Figure 47).
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Figure 45. Talin1 S425 phosphorylation promotes bone metastasis in vivo.
Luciferase-labeled PC3-MM2 sh-control, talin1-silenced, talin1WT and mutant-expressing
cells (1 × 106) were injected into nude mice intracardially. After 21 days injection,
bioluminescence and X-ray imaging of mice were performed. Images are superimposed
to localize tumor growth. Arrows indicate tumor growth in femur/tibia junction.
*Talin1WT compared with sh-talin1 or talinWT, P < 0.05.
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Figure 46. Bioluminescence imaging of luciferase-labeled talin1 mutants in mice
after intracardiac injection. Luciferase-labeled PC3-MM2 sh-control, talin1-silenced,
talin1WT and mutant-expressing cells (1 × 106) were injected into nude mice intracardially.
Shown in the figure is bioluminescence imaging of mice 21 days post-injection.
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Figure 47. Tumor burden in the femur/tibia of mice following intracardiac injection.
Tumor growth in the femur/tibia was estimated by luciferase activity of cells (presented
as photons/sec).
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Next, I examined whether talin1 phosphorylation affects lymph node metastasis
(spontaneous metastasis) of prostate cancer cells injected orthotopically into prostate.
Mice were sacrificed when primary tumors reached similar sizes (Figure 48), and lymph
node metastases were detected and counted by bioluminescence imaging (Figure 49).
Lymph node metastases developed in all groups (PC3-MM2 cells expressing talin1WT,
talin1S425A and talin1S425D mutants; Figure 49); however, as shown in Table 1,
significantly fewer lymph node metastases were observed in talin1S425A mice compared to
talin1WT mice. Together, our results are consistent with talin1 S425 phosphorylation
promoting metastasis.
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Figure 48. Representative primary tumors when mice were sacrificed and examined
for lymph node metastases. Luciferase-labeled PC3-MM2 talin1WT and mutantexpressing cells (5 × 105) were orthotopically injected into the prostate. Mice were
sacrificed when primary tumors reached similar sizes.
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Figure 49. Representative bioluminescence imaging of lymph node metastases.
Luciferase-labeled PC3-MM2 talin1WT and mutant-expressing cells (5 × 105) were
orthotopically injected into the prostate. Bioluminescence imaging of lymph node
metastases of PC3-MM2 talin1WT and mutant-expressing cells in mice after removing the
primary tumor.
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Table 1. Effects of talin1 S425 phosphorylation on development of lymph node
metastases of talin1-expressing PC3-MM2 cells injected intraprostatically
Tumor incidence
Tumor cells
Talin1WT

LN metastases
incidence

Average # of LN
metastases (range)

6/6

6/6

3 (2-4)

Talin1S425A

5/5

5/5

1.8 (1-2)*

S425D

5/5

5/5

2.8 (2-3)

Talin1

*ANOVA and Tukey’s test, talin1S425A compared to talin1WT, P < 0.01
Abbreviation: LN, lymph node.

- 110 -

Chapter 8
Talin1 phosphorylation in human prostate cancer
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This chapter is based in partly upon “Jin JK, Tien PC, Cheng CJ, Song JH,
Huang C, Lin SH, Gallick GE (2014) Talin1 phosphorylation activates β1 integrins: a
novel mechanism to promote prostate cancer bone metastasis. Oncogene (in press)” with
permission.

Talin S425 phosphorylation in human prostate cancer specimens
To determine clinical relevance of talin S425 phosphorylation in prostate cancer, I
collaborated with Dr. Sue-Hwa Lin and Dr. Chien-Jui Cheng to perform
immunohistochemical analysis on formalin-fixed human prostate tumor specimens. We
examined talin S425 phosphorylation in human primary tumors, lymph node metastases
and bone metastases. The talin S425 phospho-specific antibody used in the
immunohistochemical analysis was validated using a blocking peptide (Figure 50).
Representative images of normal glands, primary tumors, lymph node metastases and
bone metastases are shown in Figure 51. Talin phosphorylation was not detected in
normal or atrophied glands (Figure 51A), while 8 of 20 (40%) of primary tumors and 6 of
13 (46%) lymph node metastases stained positive (Figure 51B). Phospho-talin S425 was
observed in 16 of 20 (80%) bone metastases, a significant increased compared to either
primary prostate tumors (P = 0.009), or to lymph node metastases (P = 0.043; Figure
51B). There was no correlation between talin phosphorylation and Gleason score. These
data demonstrate increased talin S425 phosphorylation is associated with prostate cancer
bone metastasis.
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Figure 50. Validation of specificity of ptalin S425 antibody. PC3-MM2 cells were
pelleted to fixed in 10% formalin as described in Materials and Methods. Sections of cell
blocks were incubated with ptalin S425 antibody alone or simultaneously with
corresponding blocking peptide.
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Figure 51. Talin S425 phosphorylation in stages of human prostate cancer. (A)
Immunohistochemical staining of talin S425 phosphorylation in primary tumor, lymph
node metastases and bone metastases. Arrows indicate negative staining in atrophied
glands, and an arrow head indicates negative staining normal glands within the primary
tumor. Scale bar represents 100 µm. (B) Percentage of human specimens expressing talin
S425 phosphorylation. *Primary tumor compared to bone metastases, P < 0.005.
**Lymph node metastases compared to bone metastases, P < 0.05.
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Chapter 9
Discussion
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Cancer metastasis is a complex process involving genetic and epigenetic
alterations of cancer cells. While many oncogenes and tumor suppressor genes are
associated with cancer metastasis, epigenetic alterations, such as constitutive activation of
receptors on the plasma membrane, often deregulate signaling cascades that increase
metastatic potential of cancer cells. Integrins are cell surface receptors for various
extracellular matrix (ECM) proteins and can be activated through inside-out signaling
[174]. When aberrantly activated in cancer cells, integrin signaling promotes multiple
steps in the metastatic cascade, including increasing migration, invasion, adhesion and
survival. In prostate cancer, activation of several integrins, including α5β1, α2β1 and
αvβ3 integrins have functional consequences for prostate cancer metastasis [79, 80, 108,
111, 175-177]. By using a neutralizing anti-β1 integrin antibody (mAb 33B6), Dr. SueHwa Lin’s group demonstrated that inhibiting β1 integrins decreases cell adhesion,
migration, cell survival and downstream integrin signaling in vitro [112]. Furthermore,
treatment of the anti-β1 integrin antibody, mAb 33B6, suppressed spontaneous metastasis
of PC3-MM2 cells from the prostate to lymph nodes in SCID mice. Further, in a mouse
model of experimental metastasis, delivery of mAb 33B6 suppressed bone metastasis of
PC3-MM2 cells following intracardiac injection [112]. These data suggest that β1
integrin activation is critical for prostate cancer metastasis.

As described in the introduction, integrin activation occurs through an inside-out
mechanism or an outside-in mechanism [91, 178]. As inside-out activation rapidly
increases integrin affinity for ECM ligands, which in turn facilitates outside-in activation;
thus, the two mechanisms of integrin activation are not mutually exclusive [91]. However,
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the precise mechanism by which intracellular signaling induces inside-out integrin
activation is still unknown. Although several intracellular proteins such as talin, kindlin
and integrin-linked-kinase (ILK) are known to facilitate integrin activation, only talin can
directly bind β integrins and induce activation [179]. Cellular talin in quiescent cells
exists in a closed conformation that requires several molecular steps before assuming an
open, integrin binding conformation. However, the regulatory mechanism for talin
activation is unknown, and may occur through several different mechanisms including
binding PIP2 [135, 136], and calpain cleavage [137]. A potential mechanism not
previously studied is talin phosphorylation. Talin is heavily phosphorylated on 30
residues (serine, threonine and tyrosine). One potential important site of phosphorylation
to prostate cancer is S425 [139, 143]. Talin S425 is phosphorylated by Cdk5 whose
activity is controlled by the activator protein p35. Both Cdk5 and p35 are highly
expressed in prostate cancer and associated with metastasis [155, 156]. The talin1 linker
domain containing S425 binds the central portion of the rod domain [121], which masks
the integrin-binding domain. Thus, phosphorylation of talin1 on S425 is predicted to
promote an “open” conformation, thereby exposing the integrin-binding domain [138,
139]. However, the role of talin1 S425 phosphorylation in integrin activation was not
determined prior to studies present in this dissertation.

Therefore, I proposed a hypothesis that talin1 S425 phosphorylation promotes β1
integrin activation. Because β1 integrins are receptors for collagens, the major component
of bone, I focused on β1 integrin activation and its effect on bone metastasis. Furthermore,
I also proposed that talin is phosphorylated by Cdk5 whose activity is increased due to
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overexpression of p35 in metastatic prostate cancer cells. Next, I predicted that the
increased β1 integrin activation through talin phosphorylation can promote anoikis
resistance, adhesion and motility of cancer cells. Using various functional assays, I tested
these effects of talin phosphorylation in vitro. Collectively, gaining of these metastatic
properties through talin phosphorylation may increase metastatic potential of cancer cells.
To test this possibility, I examined metastasis of talin mutants in experimental and
spontaneous metastasis models in vivo. Finally, I determined the clinical relevance of
ptalin S425 by immunohistochemistry in human prostate cancer samples.

Activation of integrins in prostate cancer metastasis
In Chapter 3, I addressed the question whether β1 integrin activation is increased
through inside-out activation in metastatic prostate cancer cells. This question was based
on the hypothesis that β1 integrins are activated in the metastatic prostate cancer cells,
but not in low metastatic cells. To test this hypothesis, the levels of β1 integrin activation
were examined in low metastatic (LNCaP, C4-2B4) and high metastatic (PC3, PC3-MM2)
prostate cancer cells. The results from works in Dr. Sue-Hwa Lin’s labortary to which I
contributed, demonstrated that the constitutive activation of β1 integrins correlates with
metastatic potential of established prostate cancer cell lines [112].

Next, to determine whether β1 integrins were activated through inside-out
signaling in metastatic prostate cancer cells, cells were cultured in suspension without
ECM ligands to prevent integrin activation by ligand binding or cell aggregation. In this
condition, normal cells will undergo anoikis leading to cell death, but metastatic cancer
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cells often develop resistance to anoikis by increasing integrin signaling [66]. Indeed, as
shown in Chapter 3, β1 integrin activation correlated with anoikis resistance in prostate
cancer cells (Figure 12, 13 and 14). Furthermore, knockdown of β1 integrins in PC3MM2 cells increased sensitivity of cells to anoikis, which suggests that inside-out
activation of β1 integrins induces signaling that increases anoikis resistance in metastatic
prostate cancer cells. Therefore, I demonstrated in Chapter 3 demonstrated that β1
integrins are constitutively activated through inside-out activation in metastatic prostate
cancer cells.

As described in the introduction, β1 integrins have been shown to promote cell
properties critical to metastasis. My studies in Chapter 3 provide a molecular mechanism
suggesting that β1 integrins are constitutively activated through inside-out signaling.
Activation of β1 integrins in prostate cancer was also supported by immunohistochemical
staining of downstream effector, FAK. Studies from Dr. Sue-Hwa Lin’s laboratory
showed that FAK Y397 phosphorylation is increased in primary tumor and lymph node
metastases compared to normal human tissues [112]. Because phosphorylation of FAK
Y397 directly results from integrin activation, the results indicate that β1 integrin
activation occurs during prostate cancer progression. However immunohistochemical
staining of activated β1 integrins cannot be assessed in formalin-fixed clinical specimens
as antibodies that recognize activated β1 integrins in these specimens do not exist. In fact,
there are only several integrin antibodies that can specifically recognize activated
conformation of β1 integrins in cells, such as mAb 9EG7 and 12G10. There are no
commercial available antibodies for other activated integrin subunits, such as for β3.
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Accordingly, the activation of other integrins associated with prostate cancer progression
can only be assessed through activation of downstream signaling. Therefore, whether
other β integrins are also activated in prostate cancer cells remains unknown.

Currently, whether β integrins have overlapping functions or distinct functions in
promoting prostate cancer metastasis is unclear. As I demonstrated the effects of β1
integrin activation in this dissertation, β3 integrins have also been shown to increase
adhesion, migration and invasion in prostate cancer cells [180]. In fact, for β integrins
other than β1, many effects of β3 integrins, such as the ability to increase migration,
appear to be overlap with β1 integrins. Thus, the functions of β3 integrin in promoting
metastatic potential of cells may be similar to β1 integrins during prostate cancer
metastasis. Despite integrins’ functions may be similar in metastasis, integrins may be
activated in different compartments of tumor microenvironments.

In this dissertation, I only focused on the β1 subunit of integrins in prostate cancer
metastasis. Nevertheless, the α subunits of integrins are also involved in prostate cancer
metastasis. Prostate cancer cells with high expression of α6 integrins are more invasive in
a mouse model system [181]. For αv subunit, overexpression of αv integrins increases
cell adhesion and invasion in prostate cancer cells [177, 182]. In this dissertation, β1
integrins were activated to increase migration of cancer cells on collagen and promote
bone metastasis, but which α subunits pairing with activated β1 integrins is unknown.
Integrin α subunit functions to determine the binding specificity to ECM proteins. β1
integrins dimerizing with several α subunits, including α1, α2, α10 and α11, are able to
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bind collagen (Figure 3). Among those α integrins, only the α2 subunit is overexpressed
in prostate cancer and was shown to increase tumor growth in bone [79]. Therefore, α2β1
integrins could be one of the candidates to bind phosphorylated talin and become
activated in this study.

Talin1 phosphorylation regulates β1 integrin activation
The inside-out activation of β1 integrins has received less attention in cancer
research, as most studies focus on ECM-induced integrin signaling. The studies in
Chapter 3 demonstrate that inside-out activation of β1 integrins promotes anoikis
resistance, but the mechanism was unknown. Therefore, I determined the mechanism of
inside-out activation of β1 integrins in metastatic prostate cancer cells. Previous studies
demonstrate that β integrins are activated by talin binding [183]. In vertebrates, talin has
two genes, Tln1 and Tln2, that share 74% amino acid sequence similarity [184]. However,
which talin is critical to activate β1 integrins in metastatic prostate cancer was not known.
In Chapter 4, I demonstrated that talin1 is abundantly expressed in PC3-MM2 cells
compared to talin2 (Figure 18). Knockdown of talin1 reduced β1 integrin activation and
inhibited cell spreading, but this phenomenon was not observed in talin2 knockdown
cells (Figure 19, 21 and 22). In adult mice, talin1 deficiency causes abnormal embryonic
development and is embryonically lethal [185]. In contrast, talin2 knockout mice are
viable and fertile [185]. Studies using specific antibodies targeting to talin1 and talin2
reveal different subcellular localization. Only talin1 is localized in the podosomes of
adhesion structure, suggesting that talin1 has a direct function in cell-ECM interactions
[184]. A study also showed that overexpression of talin1 increases integrin signaling in

- 121 -

prostate cancer cells [114]. Therefore, the results in Chapter 4 are consistent with other
studies, suggesting that talin1 is critical for β1 integrin activation and cannot be
compensated by talin2 in metastatic prostate cancer cells.

However, when I examined the expression of talin1 in prostate cancer cells, the
immunoblotting of talin1 confirmed the result from Dr. Sue-Hwa Lin’s laboratory and
indicated that the levels of talin1 in prostate cancer cell lines did not change or correlate
with metastatic potential of these cells (Figure 23). This result was unexpected because
talin1 was shown to be overexpressed in metastases compared to primary tumor tissues in
prostate and other cancers [114-116]. While we cannot explain why talin1 expression did
not increase in metastatic prostate cancer cells, studies from other laboratories also
showed inconsistent results with respect to talin1 expression. In those studies, most
metastatic cancer cell lines did not show higher expression of talin1 compared with low
metastatic cancer cell lines, even though talin1 is overexpressed in human metastases
specimens [114, 115].

The similar levels of talin1 expression in prostate cancer cell lines indicated that a
mechanism other than talin protein level may be responsible for activating β1 integrins.
Because talin1 phosphorylation on S425 controls cell migration associated with β1
integrin signaling [143], I tested whether talin1 phosphorylation on S425 activates β1
integrins. For this reason, I examined the phosphorylated talin1 by immunoblotting and
immunoprecipitation of talin1 in prostate cancer cell lines. I again confirmed the data
from Dr. Sue-Hwa Lin’s laboratory and demonstrated that talin1 phosphorylation is
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correlated with metastatic potential of these cells (Figure 23 and 24). In addition, talin1
phosphorylation also correlated with β1 integrin activation in prostate cancer cells, which
implies a possible role of talin phosphorylation in activating β1 integrin activation.

To directly test whether talin1 phosphorylation activate β1 integrins, I generated
three plasmids encoding full-length human talin1 wild type, a non-phosphorylatable
mutant, talin1S425A, and a phosphorylation-mimicking mutant, talin1S425D. To avoid
effects from endogenous talin1, I transfected these plasmids into talin1-silenced PC3MM2 and C4-2B4 cells and selected stable transfected cells (Figure 25). By using these
cells in flow cytometric analysis and immunofluorescence staining, I demonstrated that
talin1 phosphorylation activates β1 integrins in two prostate cancer cell lines (Figure 26,
27 and 28). Furthermore, talin1 phosphorylation initiated β1 integrin signaling required to
increase cell adhesion, migration, invasion and survival in anoikis in prostate cancer cells,
but did not affect cell proliferation (Chapter 5). To my knowledge, this is the first
evidence that demonstrates talin phosphorylation is important in activation of β1 integrins.
In a previous study, Ratnikov et. al. revealed 30 phosphorylation sites on talin using mass
spectrometry [139]. Although the function of talin phosphorylation was unknown,
Ratnikov et. al. first proposed that talin phosphorylation may regulate integrin activation,
because many residues in talin head where the integrin binding site located are heavily
phosphorylated [139]. Later, the same group found that talin S425 phosphorylation
functions to prevent ubiquitylation and degradation of the talin head [143]. Up to now, no
other study has reported any function of talin phosphorylation on S425 or any other sites.
The reason may due to lack of phospho-specific antibody to other talin phosphorylation
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sites. Therefore, when new antibodies are generated, researchers may able to study the
functions of other phosphorylation sites on talin.

β1 integrins contain several alternatively spliced variants as described in the
introduction. While the β1A variant was shown to act as a stimulator of cell proliferation,
the β1C variant acted as an inhibitor for integrin signaling. Previous studies have
demonstrated that talin binds to only the β1A and β1D isoforms, but not to β1C integrins
[186]. Therefore, talin phosphorylation is likely to activate β1A or β1D integrins in
prostate cancer cells, but this possibility remains to be determined in future studies.

In this dissertation, I used full-length human talin1, because studies have shown
that only full-length talin is capable of forming focal adhesions and initiating proper
adhesion-dependent signaling [187]. Talin can be cleaved by calpain to yield a 50-kDa Nterminal head domain and a 220-kDa C-terminal rod domain. In fact, most studies only
used the talin head because it can directly bind to the β subunit and is sufficient to
activate integrins. Previously, Huang et. al. showed that the talin head phosphorylation on
S425 prevents ubiquitylation and protein degradation of the talin head [143]. However, in
my dissertation, non-phosphorylatable talin1S425A mutant was not degraded as the fulllength protein level was similar compared to that of talin1 wild type or talin1S425D
mutants (Figure 25). Perhaps, ubiquitylation of non-phosphorylated talin only occurs
after cleavage of the talin head, which remains to be determined.

- 124 -

As described in the Introduction, talin has to attain an open conformation to bind
the cytoplasmic tails of β integrins [130, 188]. Based on previous structural analyses,
full-length talin1 exists in a compact, auto-inhibited conformation with its integrinbinding domains masked [121]. Phosphorylation of talin has been proposed to relieve the
inhibitory conformation [138, 139]. In this dissertation, talin1 phosphorylation was
required to activate β integrins as shown in Chapter 4. Furthermore, in Chapter 5, talin1
phosphorylation induced β1 integrin signaling leading to changes of cell properties
related to the functions of β1 integrins. Therefore, phosphorylated talin1 may present as
an active and open conformation in order to activate integrins. However, whether
phosphorylation induces a conformational change of talin was not studied in this
discussion and is still unknown. Besides phosphorylation, several integrin-associated
proteins, including kindlin and RIAM [189, 190] also have been implicated in promoting
an open conformation of talin. Since talin also functions as an adaptor protein,
phosphorylation of talin1 may recruit those integrin-associated proteins to facilitate
integrin activation. Therefore, future studies of protein association with phosphorylated
talin1 are warranted to provide an understanding of integrin activation, and whether these
proteins or lipids binding to talin are required for its “open” conformation.

Talin1 phosphorylation by Cdk5/p35
Previous studies from Huang et. al. showed that talin1 is phosphorylated by Cdk5
in neural cells [143]. In fact, Cdk5 has been found to regulate cell adhesion and migration
in non-neuronal cells [158, 159]. A study using Cdk inhibitor, roscovitine, was able to
inhibit Cdk5 activity and β1 integrin activation in keratinocytes, which suggests that
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Cdk5 activity is associated with β1 integrin activation [159]. However, whether talin1 is
phosphorylated by Cdk5 in metastatic prostate cancer cells was unknown. Therefore, in
Chapter 6, I hypothesized that Cdk5 activity is increased in metastatic prostate cancer
cells leading to talin1 phosphorylation. First, I demonstrated that expression of p35 is
increased in PC3 and PC3-MM2 cells and correlated with increased Cdk5 kinase activity
in prostate cancer cells (Figure 38 and 39). This result is in agreement with
immunohistochemical analyses of Cdk5 and p35 from other groups. Studies showed that
when compared with human normal tissues, Cdk5 and p35 are overexpressed in primary
prostate tumors compared with normal tissues [155]. Furthermore, Strock et. al.
demonstrated that overexpression of dominant-negative Cdk5 in rat prostate cancer cells
inhibits lung metastasis in subcutaneous xenograft mice [156], which suggests that Cdk5
activity is required to promote metastatic potential of prostate cancer cells. A recent study
demonstrated that Cdk5 and p35 are clustered with talin and β1 integrins into
lamellipodia during cell spreading [160]. In agreement with this result, I demonstrated
that Cdk5 activity is required for talin1 phosphorylation, and for β1 integrin activation
(Figure 40-43). Moreover, knockdown of Cdk5 in phosphorylation-mimicking talin1S425D
cells does not significantly decrease β1 integrin activation, compared to talin1WT, which
suggests that talin1 phosphorylation is mediated in Cdk5-induced β1 integrin activation
(Figure 44). Therefore, increased p35 expression promotes Cdk5 activity in metastatic
prostate cancer cells, which further phosphorylates talin1 leading to β1 integrin activation.

Although the mechanism by which p35 is upregulated in metastatic prostate
cancer cells in this studies is unknown, defining this mechanism will provide further
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insights into how the p35/Cdk5/talin/integrin activation axis contributes to metastasis. In
rat neuroblastoma cells, TGF-β signaling has been shown to increase Cdk5 kinase
activity by upregulating p35 protein expression through induction of the transcription
factor Egr-1 [191]. In prostate cancer, TGF-β serves as a tumor promoter [192], and that
Egr-1 is also overexpressed in aggressive prostate cancer cells [193]. TGF-β also
enhances EMT, which increases the migratory capability of prostate cancer cells. One
logical possibility for p35 overexpression in metastatic prostate cancer cells is through
increased TGF-β and/or Egr-1 signaling. However, future studies are required to
determine this potential mechanism of increased p35 expression.

Talin1-phosphorylation in bone metastasis
Studies in Chapter 7 assessed the effects of talin1 phosphorylation in prostate
cancer metastasis in vivo. Using these PC3-MM2 talin1 mutants with the luciferase
expressed, I tested whether talin1 phosphorylation is required for bone metastasis
(experimental metastasis model) and lymph node metastasis (spontaneous metastasis
model). In the bone metastasis model, imaging analysis revealed no tumor growth in legs
of mice injected with talin1S425A cells (Figure 45-47). Although tumors also appeared in
the mouse heads, this phenomenon is common in this model and seems not relate to bone
metastasis [173]. These results suggest that talin1 phosphorylation is required for bone
metastasis, possibly by increasing the interaction of β1 integrins on cells with bone
stroma. During prostate cancer bone metastasis, integrin heterodimerization usage is
altered to increase interaction with ECM in the bone matrix [194]. Several â1 integrin
family proteins on prostate cancer cells have been shown to interact with both the bone
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matrix and stromal cells. For example, expression of α5β1 integrins facilitates adhesion
and spreading of PC3 cells on fibronectin [107]. Blocking α5β1 integrins by monoclonal
antibodies inhibits adhesion of DU-145 prostate cancer cell to bone marrow stromal cells
[107, 110]. Another β1 integrin family protein, α2β1, has been shown to increase
migration and adhesion of LNCaP cells on collagen I, and promotes bone metastasis in
vivo [79, 80]. Similar to α5β1, α2β1 was found to mediate adhesion of malignant tumorderived prostate epithelial cells to human bone marrow stroma, which can also be
inhibited by antibodies targeting α2β1 [111]. These results suggest that interactions
between tumor cells and bone matrix/stroma through β1 integrins are critical for tumor
cell colonization in the bone. Since talin1 phosphorylation leads to constitutive activation
of β1 integrins in metastatic prostate cancer cells, my work suggests that talin1
phosphorylation promotes bone metastasis through increasing β1 integrin activation on
cancer cells thus leading to increased interaction with bone stroma.

To understand whether talin1 phosphorylation is specific to bone metastasis, I
also examined roles of talin1 S425 phosphorylation in spontaneous lymph node
metastasis following orthotopic implantation of talin1 mutant cells. In contrast to the
effects of talin1 mutants on bone colonization, lymph node metastases were observed in
mice injected with cells expressing wild-type and talin1S425A that is unable to activate β1
integrins (Figure 48 and 49). Although the number of lymph node metastases in
talin1S425A was decreased, incidence of lymph node metastasis was not changed (Table 1).
Our results were consistent with a recent study of Barthel et al. who found that β1
integrins were highly activated in prostate cancer cells derived from bone metastasis, but
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not in LNCaP variants selected form lymph node metastasis [175]. Therefore, these
results imply that β1 integrins are less important to lymph node metastasis than to bone
metastasis [175]. However, my results do support that β1 integrin activation does, in
general, promote prostate cancer metastasis.

The results in Chapter 7 demonstrated that inside-out β1 integrin activation is
required for prostate cancer bone metastasis. As described in the introduction, integrin
signaling through inside-out and outside-in direction are not separate events in cells,
because the two mechanisms of integrin activation interact with one another. Therefore,
outside-in β1 integrin signaling through binding ECM proteins may also contribute to
bone metastasis in vivo. Previous studies from Dr. Sue-Hwa Lin’s laboratory
demonstrated that blocking of β1 integrin binding with ligands using an anti-β1 integrin
antibody (mAb 33B6) decreased cell adhesion on ECM matrix. Treatment of mAb 33B6
reduced metastatic tumor growth in bone in vivo [112]. In addition, from my studies in
Chapter 5, β1 integrin activation through talin phosphorylation increased ECM binding as
cells strongly adhered on collagen-coated matrix. These data suggest that integrin
outside-in signaling through binding ECM proteins is equally important for bone
metastasis. Prostate cancer cells with activated β1 integrins through talin phosphorylation
are likely binding bone ECM proteins, which facilities colonization of cancer cell in the
bone.

Finally, to support the finding of talin1 phosphorylation in prostate cancer bone
metastasis, I collaborated with Dr. Sue-Hwa Lin and Dr. Chien-Jui Cheng to examine
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talin phosphorylation in human tissues. Using an antibody specific to phospho-talin S425,
we demonstrated that talin phosphorylation is more highly expressed in bone metastases
than in lymph node metastases or primary tumors, with no talin phosphorylation observed
in normal or atrophied (non-tumorigenic) glands (Figure 51). Therefore, these data are
consistent with our in vivo studies and provide a clinical evidence that talin S425
phosphorylation is critical for prostate cancer bone metastasis.

Integrins, talin1 and Cdk5 as therapeutic targets
Integrins
Targeting integrins using inhibitory antibodies is a logical approach to inhibit
aberrant integrin signaling in cancer cells. In studies from Dr. Sue-Hwa Lin’s laboratory,
using neutralizing antibody mAb 33B6 successfully inhibited metastasis of prostate
cancer cells in mice [112]. In fact, other functional blocking β1 integrin antibodies such
as mAb AIIB2 and JB1a have been shown to inhibit tumor growth and metastasis in
breast cancer [195, 196]. Therefore, targeting β1 integrins by antibodies has great
potential to affect tumor growth and/or metastasis in prostate cancer. Currently, many
integrin antibodies are being developed for several diseases including solid tumors [197].
For example, the M200 Volociximab, an anti-α5β1 integrin antibody, was used in a
clinical trial (phase II) to assess the effect to patients with various solid tumors [198]. A
panel of integrin antibodies targeting αvβ3, including MEDI-522 (phase II), CNTO95
(phase II) and Cilengitide (phase II) was evaluated for the effects of integrin-mediated
angiogenesis in patients with metastatic CRPC [199]. Results from these studies will
hopefully lead to better treatment strategies for prostate cancer. A concern of integrin-
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targeting therapy is the potential overlapping in integrin functions; therefore biomarkers
that identify which integrins are activated to target would be important to optimal antiintegrin therapy.

Talin
Although talin1 may not be a druggable target for prostate cancer, talin1
phosphorylation may be used as a biomarker for integrin activation in prostate cancer
bone metastases. From the results in chapter 8, talin is highly phosphorylated in prostate
cancer bone metastases compared with lymph node metastases or prostate tumors. Thus,
talin phosphorylation may be a useful biomarker for bone metastasis. Recently, a study
found that talin1 is presented in the serum samples from patients with hepatocellular
carcinoma, and the serum level of talin1 is significantly higher compared to the healthy
group [200]. Phosphorylated talin1 may also present in the serum from prostate cancer
patients with bone metastasis. Another possible approach to detect phosphorylated talin1
is to isolate circulating tumor cells (CTCs) from prostate cancer patients. Although
whether talin is phosphorylated in CTCs is unknown, the talin1S425D mutant cells were
resistant to anoikis as shown in chapter 5, which suggests that talin1 phosphorylation may
be required for CTCs to survive in the circulation. Therefore, talin1 phosphorylation in
prostate CTCs may be a potential biomarker for prognosis in patients.

Cdk5
As increased Cdk5 activity was showed responsible for talin1 phosphorylation in
this study, targeting talin phosphorylation through inhibiting Cdk5 activity will be a
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reasonable strategy to develop prostate cancer therapy. In chapter 6, talin1
phosphorylation was inhibited by Cdk inhibitor, roscovitine (Figure 40). Therefore,
treatment of a selective Cdk5 inhibitor should inhibit β1 integrin activation in prostate
cancer cells as well as cancer metastasis. However, no selective Cdk5 inhibitor has been
developed to date. The (R)-roscovitine or Seliciclib/CYC202 is current being evaluated in
clinical trials for antitumor activity in advanced solid tumors [201]. Although roscovitine
has an inhibitory effect on Cdk5 activity, it can also inhibit other Cdks, including Cdk1
and Cdk2. Therefore, developing a more selective Cdk5 inhibitors would be necessary to
explore the effect of Cdk5 in prostate cancer metastasis.

Future perspectives
This dissertation clarified the role of many proteins implicated in prostate cancer
metastasis. While p35, Cdk5, talin and integrins have all been associated separately in
increasing metastatic potential, my work is the first to put them together in a single
pathway. This dissertation further demonstrated the role of talin phosphorylation as a
regulator for β1 integrin activation (Figure 52). However, many questions remain to be
determined in the future. Bone microenvironment is known to facilitate cancer cell
colonization and tumor growth. This dissertation demonstrated that β1 integrin activation
on cancer cells facilitates metastasis of prostate cancer cells in the bone. Therefore, future
studies should focus on determining the interaction between cancer cells and the bone
microenvironment. Generally, studies are needed to determine what is the role of β1
integrin activation in the bone microenvironment during prostate cancer metastasis. Do
β1 integrins on cancer cells affect bone cells or bone remodeling? On the other hand, do
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bone cells affect β1 integrin activation on cancer cells? While α and β subunits of
integrins control ligand specificity, it may be necessary to identical which α subunit is
pairing with β1 integrins. In addition, whether β1 integrins heterodimerize with particular
α subunits in different stages of prostate cancer progression? The answers to these
questions will provide important information for understanding prostate cancer bone
metastasis.

In this dissertation, talin phosphorylation promoted integrin activation leading to
metastasis. However, cancer metastasis involves multiple mechanisms that are required to
change cell properties, and integrin activation could be just one of them. Another
mechanism that is possibly involved in integrin activation is epithelial plasticity. As
mentioned in the introduction, EMT is required for increasing cancer cell motility. In our
results, talin1 phosphorylation increased migration and invasion in C4-2B4 cells, which
implies that EMT may also occur during integrin activation. In fact, studies have shown
that expression of β1 integrins enhances EMT in non-small cell lung cancer cells [202].
In breast cancer cells, αvβ1 and αvβ6 integrins also induce EMT after treated with an
ECM protein, tenascin. Therefore, whether talin1 phosphorylation can induce ECM
should be determined in the future studies.

A difficult question regarding epithelial plasticity is the role of integrin activation
in MET. If β1 integrin activation can induce EMT in the primary tumors, cancer cells in
bone metastases should have MET and inactive β1 integrins. However, according to our
clinical date, talin was mostly phosphorylated in the bone metastases, suggesting that β1
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integrins are still activated in these tissues. Therefore, further studies should determine
whether β1 integrins on cancer cells are not required for MET to occur. Furthermore,
MET can explain why cancer cells in the metastatic sites show similar epithelial
phenotypes as epithelial tumor at the primary site. Therefore, other integrins which are
highly expressed in the primary site may also show higher expression in the bone
metastases.

Because talin1 has been shown to activate β3 integrins [124], whether talin1
phosphorylation can activate β3 integrins in prostate cancer cells also remains to be
determined. In addition to the roles of β1 integrins, β3 integrins may also have roles in
tumor growth in the bone. β3 integrins specifically bind to bone ECM proteins such as
osteopontin and bone sialoprotein. In my studies, talin1 phosphorylation did not affect
cell proliferation, suggesting that β1 integrins may be not responsible for prostate cancer
cell proliferation (Figure 30). Thus, inside-out activation of β3 integrins may increase the
binding of these bone ECM proteins and promote tumor growth in the bone.

For talin phosphorylation, a difficult question to answer is how phosphorylation
of talin structurally induces β1 integrin activation? Because talin1 has to be activated
prior to activate β1 integrins, it is plausible that phosphorylation may induce a
conformational change in talin1 leading to talin1 activation. To test this hypothesis,
protein structure modeling analyses may be useful to predict the conformational change
of phosphorylated talin1. However, the interaction between phosphorylated talin1 and β1
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integrins may be more complex than we thought, and these analyses are likely to be
difficult due to the other 30 phosphorylation sites also present in talin.

Although this dissertation focused on motility and survival of cancer cells,
integrins affect other properties of cancer cells. One of the major problems in cancer
therapy is developing drug resistance in cancer cells. Treatments of kinase inhibitors for
prostate cancer usually develop drug-resistance, which has been shown due to increased
β1 integrin signaling [84]. Indeed, studies have shown that β1 integrin signaling is
increased to activate PI3K/Akt survival pathway for developing resistance to cytotoxic
chemotherapies [86]. In addition, β1 integrin expression is increased upon exposure to
ionizing radiation, which has been suggested to be a mechanism for therapy resistance
[87]. From this dissertation, β1 integrin signaling was shown constitutively activated in
metastatic prostate cancer cells. Therefore, β1 integrins may play an important role in
therapy resistance and may control recurrence of metastasis. Thus, targeting β1 integrins
together with kinase inhibitor may be a better strategy to treat prostate cancer.
Furthermore, cancer cells metastasized into the distant organs usually enter into a period
of dormancy or senescence and form micrometastases. Studies have shown that β1
integrin signaling is required to break the dormancy in cancer cells [84]. Therefore, talin1
phosphorylation and β1 integrin activation may play roles in escaping senescence and
resuming proliferation of cancer cells leading to tumor growth in the bone.
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Conclusions
In this dissertation, I demonstrated the importance of talin1 S425 phosphorylation
for inside-out activation of β1 integrins and promotion of prostate cancer bone metastasis.
In metastatic prostate cancer cells, β1 integrins are constructively activated through
inside-out integrin activation, which correlated with metastatic potential of cells. The
levels of talin1 S425 phosphorylation, but not total talin1, also correlate with metastatic
potential of prostate cancer cell lines. Besides, talin phosphorylation is significantly
increased in human bone metastases compared to primary tumors or lymph node
metastases. Using phosphorylation-mimicking and non-phosphorylatable talin1 mutants,
I demonstrated that talin1 phosphorylation is required for β1 integrin activation in
metastatic prostate cancer cells. Talin1 phosphorylation on S425 plays an important role
in cell adhesion, migration, invasion, and anoikis in vitro and metastasis of prostate
cancer cells to bone in vivo. Mechanistically, I demonstrated that Cdk5 activity is
increased in highly metastatic prostate cancer cells as compared to low metastatic
prostate cancer cells. In addition, increased Cdk5 activity in metastatic prostate cancer
cells is due to overexpression of p35. Furthermore, talin1 phosphorylation is required for
Cdk5-induced β1 integrin activation. In summary, I identified a novel mechanism for β1
integrin activation through Cdk5-mediated talin1 S425 phosphorylation in metastatic
prostate cancer cells (summarized in Figure 52). Therefore, I conclude that integrins,
talin1, Cdk5 and p35 could be potential targets for development of novel therapies for
prostate cancer bone metastasis.
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Figure 52. Model of β1 integrin activation by talin1 S425 phosphorylation in
metastatic prostate cancer cells. (1) Expression of p35 is increased in tumor cells of
high metastatic potential, which increases Cdk5 activity leading to talin1 phosphorylation.
Phosphorylation of talin1 on S425 may induce a conformational change leading to talin1
activation. Binding of additional proteins may facilitate this conformational change. (2)
Phosphorylated talin1 binds to the cytoplasmic tail of β1 integrin and (3) increases β1
integrin activation and (4) promotes integrin signaling, leading to increased survival,
adhesion, motility and metastatic potential in prostate cancer cells.
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Propidium iodide staining for FACS Analysis

1. Trypsinize cells and centrifuge cell suspension.
2. Add 5 ml of PBS and centrifuge cells at 500 ×g for 5 min.
3. Add 5 ml of 70% ethanol (cold). Make sure that cells are dispersed in the ethanol and
not clumpy. If clumpy, gently disperse cells using a pipetman.
4. Leave cells in ethanol at 4 ℃ overnight for fixing.
5. Spin cells at 500 ×g for 5 min and resuspend cells in 5 ml PBS.
6. Resuspend cells in 50 µl PBS, plus 3.3 µL RNAse (30 mg/mL) and incubate at 4°C
for 5 min.
7. Add 450 µl PBS and 25 µl PI (1 mg/ml). Incubate at 4 ℃ for 30 min.
8. Analysize immediately after incubation at 4 ℃, in order to prevent clumping of the
cells.
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Subcloning talin1 from pEZ-M29 to pWPXL-GFP plasmid

1. PCR amplify talin1 DNA fragment using pEZ-M29-talin1 plasmid as a temple,
primer set 5’GCTGTACAAGTCCGGCATGGTTGCACTTTCACTGAAGA3’
(primer #1) and 5’GAGATCTGAGTCCGGACAAGAAAGCTGGGTTGCG3’
(primer #2) and Phusion hot start II DNA polymerase (Thermo Scientific).
2. PCR reaction setup:
Water

31µl

GC buffer

10µl

10 mM dNTP

1µl

10 µM primer #1

2.5µl

10 µM primer #2

2.5µl

50 ng DNA

2 µl

DNA polymerase

1µl

Total volume

50 µl

3. Cycling: after initial denaturation, 98℃ 10 sec, 68℃ 10sec, 72℃ 1 min: 56 sec for
29 cycles then 72℃ 5 min.
4. Digested pWPXL-GFP using BspEI enzyme (Thermo Scientific) at 55 ℃ for 30
min, and then purify DNA fragments of full length pWPXL-GFP.
5. Incubate 4 µl partial-digested pWPXL-GFP and 4 µl talin1 PCR product with 2 µl
of 5× In-Fusion HD enzyme premix at 50℃ for 15 min.
6. Continue to the transformation procedure according to manufacturer’s instructions.
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Mutagenesis of talin1 on S425

1. PCR amplify whole pEZ-M29-talin1 plasmid using complementary mutagenic
primer set 5’GACTCAGTGGCCCCCAAAAAGTCAACAGTCCTG3’ and
5’GGGCCACTGAGTCCTCCAGCATAGTAGACTCCTC3’ (underline denotes
mutated site) for talin1S425A mutation. For talin1S425D mutation, using mutagenic
primer set: 5’GACTCAGTGGACCCCAAAAAGTCAACAGTCCTG3’ and
5’GGTCCACTGAGTCCTCCAGCATAGTAGACTCCTC3’.
2. PCR reaction setup:
Water

31µl

GC buffer

10µl

10 mM dNTP

1µl

10 µM primer #1

2.5µl

10 µM primer #2

2.5µl

50 ng DNA

2 µl

DNA polymerase

1µl

Total volume

50 µl

3. Cycling: after initial denaturation, 98℃ 10 sec, 59℃ 10sec, 72℃ 3 min: 30 sec for
29 cycles then 72℃ 10 min.
4. To recircularize plasmid, incubate 1 µl talin1S425A/D PCR product with 2 µl of 5×
In-Fusion HD enzyme premix and 7 µl water at 50℃ for 15 min.
5. Continue to the transformation procedure according to manufacturer’s instructions.
6. The pEZ-M29-talin1S425A/D plasmids were used as temples to PCR amplify full
length talin1S425A/D fragments and subclone into BspEI partial-digested pWPXLGFP vector according to the subcloning protocol.
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Plasmid: pEZ-M29-talin1
OmicsLink Expression Clone of EX-R0040-M29
Catalog No.: EX-R0040-M29
Accession No.: AF078828

ORF Length: 7626 bp

Whole Plasmid Size: 13791 bp
Description: Homo sapiens talin mRNA, complete cds.
Vector: pEZ-M29

Antibiotic:

Ampicillin

Stable Selection Marker: Neomycin
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Plasmid: pWPXL-GFP
Addgene plasmid: 12257
Whole Plasmid Size: 10510 bp
Antibiotic: Ampicillin
Stable Selection Marker: GFP
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Plasmid: pWPXL-GFP-talin1WT
Whole Plasmid Size: 18172 bp
Antibiotic: Ampicillin
Stable Selection Marker: GFP
Plasmid: pWPXL-GFP-talin1S425A
Mutation on 5539-5541 (TCC to GCC) in pWPXL-GFP-talin1WT plasmid to replace
serine with alanine on 425 amino acid.
Plasmid: pWPXL-GFP-talin1S425D
Mutation on 5539-5541 (TCC to GAC) in pWPXL-GFP-talin1WT plasmid to replace
serine with aspartic acid on 425 amino acid.
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Fixed cell pellet and embedded in paraffin

1. Pellet cells by centrifugation 400 ×g for 10 minutes at room temperature.
2. Resuspend cells in 10 ml 10% buffered Formalin, and fix for two hours at room
temperature.
3. Pellet cells by centrifugation 400 ×g for 10 minutes at room temperature.
4. Resuspend cells in 300 µl of PBS in a microtube.
5. Prepare 3% low melting point (LMP) agarose in PBS; weigh before microwaving.
6. Melt in microwave and replace lost water.
7. Place melted agarose mixture in water bath at 65 ℃. Allow agarose to equilibrate to
65 ℃ (about 30 minutes).
8. Heat microtube with cells in it to 65 ℃ for no more than 10 minutes.
9. Working in water bath, add 600 µl of agarose mixture to cells, and mix by pipetting
up and down.
10. Immediately transfer microtube to a room temperature microcentrifuge, and spin at
2000 ×g for five minutes.
11. Place microtube on ice, remove gelled pellet, and trim of excess agarose.
12. Wrap pellet in lens paper, place in a paraffin processing cassette, and process to
paraffin block.
http://www.umassmed.edu/morphology/protocols/fixcellpellet.aspx
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